| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
DarioHealth Corp.$7.17
-0.11 (-1.51%)
D 28Pipeline Score MedTech · Commercial
Market Cap
57.48 M
EPS
-10.58
P/E Ratio
-
Value Trade
52.61 K
SEC Financials
Q1 2026Dilution Risk
Revenue
5.58 M
R&D Expenses
2.38 M
Operating CF
-6.03 M
Total Assets
103.28 M
Total Liabilities
103.28 M
Equity
62.38 M
D/E Ratio
12,345
-6.37 %
Week
7.97 %
1 Month
-34.5 %
3 Month
-43.62 %
6 Month
-97.82 %
5 Year
-99.46 %
All Time
Cash Data
Cash Position
20.01 M
Monthly Burn
2.01 M
Runway
8.3 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
12.21 K
52 Week Range
5.94 - 17.74
% held by Insiders
20.36 %
% held by Institutions
11.62 %
Enterprise Value
69.03 M
Total Shares
7.30 M
Short %
1.37 %
Float Shares
5.59 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D28
Pipeline Score $49M
Pipeline ValueValuation Signal
1
Drugs Scored0.9x
rNPV / MCap Top 30%
Micro Cap (rank 635 of 906)
Percentile RankDarioHealth Corp. faces pipeline headwinds (28/100), with $883M risk-adjusted pipeline value, led by skin in Post-surgery Radiotherapy (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| skin Small molecule | Post-surgery Radiotherapy | Phase 3 | NCT02741258 | 50% | $883M | COMPLETED | 164 | - | - | Dec 31, 2021 | - | Jul 5, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Dario | Type 2 Diabetes | — | 2023-10-17 | hospital readmission reduction: 36%; hospital days reduction: 1.6; Hb A1c control improvement: 9%; poor control reduction: 13% Read More | New Research Shows 36% Reduction in 30-Day Hospital Readmission Rate for Dario Users with Type 2 Diabetes Read More | |
Dario | Type 2 Diabetes | — | 2023-10-17 | hospital readmission reduction: 36%; hospital days reduction: 1.6; Hb A1c control improvement: 9%; poor control reduction: 13% Read More | New Research Shows 36% Reduction in 30-Day Hospital Readmission Rate for Dario Users with Type 2 Diabetes Read More | |
Dario | Type 2 Diabetes | — | 2023-10-17 | hospital readmission reduction: 36%; hospital days reduction: 1.6; Hb A1c control improvement: 9%; poor control reduction: 13% Read More | New Research Shows 36% Reduction in 30-Day Hospital Readmission Rate for Dario Users with Type 2 Diabetes Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DRIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DRIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DRIOTop National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy
DarioHealth Corp. has expanded its partnership with a major U.S. health insurer, adding hypertension solutions to its existing behavioral health offerings. This extension is expected to triple revenue opportunities under this customer relationship, reinforcing Dario's multi-condition care strategy. The company aims to improve health outcomes while reducing costs through integrated care solutions.
Read more →DRIODario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform
DarioHealth Corp. presented notable findings at the American Diabetes Association Scientific Sessions, showcasing the effectiveness of its digital health platform in managing chronic conditions like diabetes and obesity. The studies highlighted that sustained engagement with the platform leads to improved clinical outcomes, as evidenced by significant weight loss and reductions in hospitalizations among high-risk patients. Findings indicate potential cost savings for payers and a compelling case for enterprise buyers to adopt integrated solutions for better patient management across multiple chronic conditions. With a total of 27 studies presented over eight years, Dario reinforces its strategic move towards value-based healthcare.
Read more →DRIODario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching Greater Than 500,000 Eligible Lives
DarioHealth Corp. has expanded its hypertension program through a partnership with Solera Health, significantly increasing its addressable market to over 500,000 eligible lives. This initiative targets a broader population, including pre-hypertensive individuals, and aligns revenue with clinical outcomes. DarioHealth's capabilities in engaging members and delivering value across cardiometabolic conditions are emphasized as key strengths.
Read more →DRIODarioHealth Reports First Quarter 2026 Financial and Operating Results
DarioHealth Corp. reported its first quarter 2026 financial results, highlighting a second consecutive quarter of sequential revenue growth and reduced operating expenses. The company is expanding its channel partner ecosystem, now reaching over 116 million covered lives. However, it faced a year-over-year revenue decline due to the non-recurrence of previous revenues. Despite operational improvements, the net loss increased compared to the prior year.
Read more →DRIODarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026
DarioHealth Corp. will announce its financial results for Q1 2026 on May 13, 2026. The company will host a conference call at 8:30 a.m. ET, featuring key executives. The call will be accessible via dial-in and webcast, with a replay available post-event. DarioHealth focuses on digital therapeutics for chronic conditions.
Read more →DRIODario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research
DarioHealth Corp. announced a study published in JMIR Formative Research, showing significant improvements in workplace functioning through its digital behavioral health program. The study involved 1,254 users and demonstrated enhanced focus, productivity, and task completion. These findings underscore the economic benefits of Dario's solutions for employers and health plans, addressing the link between behavioral health and workforce productivity.
Read more →DRIODario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling
DarioHealth Corp. has appointed John R. Palumbo to its Board of Directors to aid in commercial scaling. With over 40 years of healthcare experience, Palumbo's strategic insights and industry relationships are anticipated to enhance Dario's growth trajectory. His background includes leadership roles in major healthcare organizations, making him a valuable asset as Dario aims to expand its market presence.
Read more →DRIODarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
DarioHealth Corp. reported its financial results for the fourth quarter and full year of 2025, highlighting a sequential revenue increase to $5.2 million and a full-year revenue of $22.4 million. The decline in annual revenue was attributed to the non-renewal of a large client post-Twill acquisition, but the company noted substantial growth in contracted annual recurring revenue, projecting strong growth into 2026 and 2027. The financial results also revealed improved gross margins and a substantial reduction in operating expenses, with a focus on expanding commercial opportunities and new agreements signed. Overall, DarioHealth's pipeline and operating trends suggest a positive outlook despite challenges in annual revenue figures.
Read more →DRIODarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026
DarioHealth Corp. will release its financial results for the fourth quarter of 2025 on March 19, 2026, ahead of the market opening. The announcement includes details for a conference call and webcast scheduled for 8:30 a.m. Eastern Time, featuring executive leadership. The call will discuss DarioHealth's performance and business outlook, marking an important event for stakeholders. A replay option will be available for those unable to attend the live event.
Read more →DRIODario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health
DarioHealth Corp. announced the publication of a peer-reviewed study in Frontiers in Digital Health, revealing significant blood glucose improvements among over 22,000 users of its platform. The research utilized machine learning to analyze real-world data and found a strong correlation between digital engagement and health outcomes. Key insights suggest that users monitoring their glucose regularly experienced better results, allowing for personalized diabetes management strategies. The findings confirm Dario's ability to drive measurable clinical impact through tailored health solutions.
Read more →DRIODario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight Management
DarioHealth Corp. has reported a growing demand for its digital health solutions tailored for oral GLP-1 therapies. With 79% of its members utilizing weight management support, Dario aims to optimize medication outcomes through structured behavioral reinforcement. As oral GLP-1s are expected to capture a significant market share, Dario's approach focuses on enhancing adherence and long-term health outcomes for users.
Read more →DRIODario Surpasses 100 Scientific Studies, Cementing Leadership Among Digital Health's Most Evidence-Based Platforms
DarioHealth Corp. has announced a significant milestone by surpassing 100 scientific studies, including peer-reviewed publications. This achievement positions Dario among the leading digital health vendors, emphasizing its commitment to delivering validated outcomes. The company’s research is distinguished by its scientific rigor, appealing to organizations seeking measurable impacts in health delivery.
Read more →DRIODario Launches DarioIQ™ AI Integration in Dario Health App with Direct-to-Consumer First Version for Hypertension Members
DarioHealth Corp. has launched the Dario Health app with DarioIQ™, an AI integration aimed at enhancing user experience for hypertension management. This marks a significant milestone in Dario's GenAI roadmap, focusing on patient safety and personalized guidance. The initial rollout will help refine the AI experience before expanding to other chronic conditions.
Read more →DRIODario's Data-Driven Digital Health Platform Delivers Significant and Sustainable Improvements in Blood Pressure: Findings Published in JMIR Cardio
DarioHealth Corp. announced a peer-reviewed study published in JMIR Cardio, demonstrating that their data-driven digital health platform significantly improves blood pressure outcomes. The study found that users receiving digital nudges experienced a greater reduction in systolic blood pressure compared to a control group. This evidence suggests that personalized digital interventions can effectively manage hypertension over the long term.
Read more →DRIODarioHealth Far Exceeds 2025 New Client Target with 79 New Accounts Signed Year-to-Date
DarioHealth Corp. has signed 79 new employer clients in 2025, surpassing its target of 40 by 98%. The recent additions, including 34 new clients in two weeks, are expected to contribute to revenue starting in Q1 2026. The company's integrated digital health platform addresses cardiometabolic conditions, showcasing its effectiveness and market demand.
Read more →DRIODarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year
DarioHealth announced a peer-reviewed study published in JMIR, demonstrating that its digital health platform significantly reduces healthcare costs and utilization for diabetes management. The study found that Dario users experienced lower hospitalization rates and medical charges compared to those receiving usual care. This rigorous analysis supports the effectiveness of Dario's integrated digital solutions in improving chronic condition management.
Read more →DRIODarioHealth Reports Third Quarter 2025 Financial and Operating Results
DarioHealth Corp. reported its third-quarter financial results for 2025, highlighting a strategic shift towards a high-margin recurring revenue model. Despite a revenue decline to $5.0 million, the company is experiencing improved gross margins and reduced operating expenses. Dario's commercial pipeline is robust, with expectations for significant growth in 2026. The company also engaged a financial advisor in response to unsolicited interest, indicating potential future opportunities.
Read more →DRIODarioHealth Presents New Data Demonstrating Significant Reduction in Medical Costs Among Employer Populations Using Its Digital Health Platform
DarioHealth Corp. presented new research at ISPOR Europe 2025, showcasing significant reductions in medical costs among employer populations using its digital health platform. The study highlights the economic impact of Dario's multi-condition platform, particularly among high-risk members. This marks a critical milestone in demonstrating the value of digital health solutions in real-world settings.
Read more →DRIODarioHealth to Report Third Quarter 2025 Results on Thursday, November 13, 2025
DarioHealth Corp. will announce its financial results for the third quarter of 2025 on November 13, 2025. The company will host a conference call at 8:30 a.m. ET, featuring key executives. This event aims to provide insights into the company's performance and future outlook.
Read more →DRIODario Signs 6 New Employer Clients Representing Tens of Thousands of Lives Deepening its Leadership in Value-Based Care
DarioHealth Corp. has announced the addition of six new employer clients, highlighting the growing demand for its multi-condition digital health platform. The company has introduced an innovative pricing model that aligns payments with member engagement and clinical outcomes. This strategy aims to enhance value-based care while providing significant cost savings for employers. Dario's platform is designed to support employees with various chronic conditions, further solidifying its leadership in the digital health market.
Read more →DRIODarioHealth and OneStep Announce Strategic Collaboration to Integrate Smartphone-Only, Clinical-Grade Fall Risk Assessment Technology into Dario's Digital Health Multi-Condition Platform
DarioHealth has partnered with OneStep to integrate smartphone-based fall risk assessment technology into its digital health platform. This collaboration aims to enhance outcomes for high-risk populations, particularly those with obesity and frailty. The integration is expected to provide immediate insights into fall risks, potentially reducing medical costs associated with falls.
Read more →DRIODarioHealth Announces Strategic Review Following Multiple Unsolicited Inbound Expressions of Interest
DarioHealth Corp. has initiated a strategic review to maximize shareholder value following multiple unsolicited inquiries. The Board has formed a Special Committee and engaged Perella Weinberg Partners as financial advisors. The review will explore various options, including potential mergers or continued standalone strategies. No timeline has been set for the review's conclusion.
Read more →DRIODarioHealth Announces $17.5 Million Private Placement of Common Stock Priced At-The-Market Under Nasdaq Rules
DarioHealth Corp. has announced a private placement of 2,713,180 shares of common stock, priced at $6.45 each, aiming to raise approximately $17.5 million in gross proceeds. The offering is set to close around September 23, 2025, pending customary closing conditions. The funds will be utilized for general corporate purposes. This private placement leverages an exemption from standard registration requirements under US securities law.
Read more →DRIODarioHealth Issues Shareholder Update: Multi-Condition Leadership in Momentum Driven Digital Health Market
DarioHealth Corp. issued a shareholder update highlighting its leadership in the digital health market, focusing on multi-condition management. The company reported an increase in its commercial pipeline to $67 million, fueled by partnerships with third-party administrators. Additionally, DarioHealth's solutions demonstrate proven outcomes, including significant savings and reduced healthcare utilization across its patient base. Overall, these developments position DarioHealth to capitalize on the growing demand for value-based care in the healthcare landscape.
Read more →DRIODario Secures Five New Employer Contracts Across Cardiometabolic Suite Including its Largest Employer to Date, Contributing to Annual Recurring Revenues Beginning Q3 2025
DarioHealth Corp. has announced the launch of five new employer contracts covering 107,000 lives, contributing to its growing annual recurring revenues starting in Q3 2025. The new contracts emphasize Dario's multi-condition digital health solutions, which are effective for chronic conditions like diabetes and hypertension. The company indicates a strong demand for its services, highlighted by a robust pipeline valued at $67 million. Dario’s management remains optimistic about achieving 40 new client signings by year-end 2025, representing a significant increase from the previous year.
Read more →DRIODarioHealth Announces 20-to-1 Reverse Stock Split
DarioHealth Corp. announced a 20-for-1 reverse stock split of its common stock, effective August 28, 2025. This action, approved by the company's board and stockholders, will reduce the number of outstanding shares while maintaining the company's authorized share count. The split will not affect stockholders' ownership percentages or voting powers. The company aims to improve its market position with this strategic decision as it continues its operations in the global digital health market.
Read more →DRIODarioHealth Reports Second Quarter 2025 Financial and Operating Results
DarioHealth Corp. reported its financial results for the second quarter of 2025, revealing revenues of $5.4 million, which fell below expectations and marked a decline from previous quarters. The company attributes this dip to a shift in contracts with a national health plan and longer onboarding timelines for new clients. However, Dario highlighted strong client momentum with several new contracts expected to contribute to future growth, and they have maintained healthy gross margins at 55%. The outlook suggests that while the company is facing short-term headwinds, its strategic focus on building recurring revenue could lead to improved performance in the upcoming quarters.
Read more →DRIODarioHealth to Report Second Quarter 2025 Results on Tuesday, August 12, 2025
DarioHealth Corp. (Nasdaq: DRIO) has announced its plans to report financial results for the second quarter of 2025 on August 12, 2025, before market opening. A conference call and webcast will be hosted at 8:30 a.m. Eastern Time to discuss these results. Key executives, including the CEO and CFO, will be present to provide insights. The company continues to position itself as a leader in personalized digital health solutions for chronic conditions.
Read more →DRIODario and GreenKey Health Announce Strategic Commercial Agreement to Transform Chronic Condition Management and Sleep Health for Payers Nationwide
DarioHealth Corp. has entered a strategic commercial agreement with GreenKey Health to enhance chronic condition management and sleep health across the U.S. The collaboration intends to address the substantial sleep apnea market, which affects over 29 million Americans. By combining Dario's digital health solutions with GreenKey's expertise in sleep health, the two companies aim to provide comprehensive care that integrates behavioral, sleep, and cardiometabolic health. This initiative is designed to improve patient outcomes while simultaneously reducing healthcare costs and increasing productivity for payers.
Read more →DRIODario Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings
DarioHealth Corp. announced significant findings related to GLP-1 medication and AI-powered personalization at the recent American Diabetes Association conference. Their research showed a remarkable drop in average blood glucose levels among GLP-1 users, with sustained results even after medication cessation. Additionally, the AI study demonstrated high predictive accuracy for future glucose levels, indicating Dario's potential to deliver enhanced diabetes care. The company is actively pursuing commercial opportunities leveraging these findings to better support chronic condition management.
Read more →DRIODarioHealth Reports First Quarter 2025 Financial and Operating Results
DarioHealth Corp. reported its financial results for Q1 2025, showing a 17% year-over-year revenue increase to $6.75 million, although this was an 11% decrease sequentially. The company improved its gross margins and reduced operating expenses significantly, reflecting operational discipline and cost management strategies. Despite challenges like client shifts and tariff-related delays impacting project timelines, Dario signed 14 new clients and is positioned to achieve operational cash flow breakeven by the end of 2025.
Read more →DRIODario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations DarioHealth Corp. (NASDAQ: DRIO) ( Dario or the Company ), a leader in the global digital health market, announced today new research published in...
DarioHealth Corp. recently published research in the Journal of Medical Internet Research highlighting the success of its digital health solution in increasing flu vaccination awareness among diabetes patients. The study involved a randomized approach with personalized digital messaging, resulting in significantly higher vaccination rates in participants. Dario's findings emphasize the effectiveness of tailored interventions in healthcare, showcasing how digital health solutions can positively alter patient behavior and improve health outcomes.
Read more →DRIODarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025
DarioHealth Corp. (Nasdaq: DRIO) has announced that it will report its financial results for the first quarter of 2025 on May 14, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results. DarioHealth continues to position itself as a leader in the digital health market by offering a multi-chronic condition digital therapeutics platform designed for user-centric health management.
Read more →DRIODarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives
DarioHealth Corp. has successfully closed a strategic refinancing of its existing debt facility, securing up to $50 million aimed at offering operational flexibility and supporting its growth initiatives. The arrangement includes an initial $32.5 million, with additional funding contingent on revenue performance. Furthermore, the debt repayment timeline has been extended from 2025 to 2028, allowing the company more time to generate operational funds. This refinancing is intended to enhance Dario's ability to execute its Business-to-Business-to-Consumer strategy effectively in the evolving digital health landscape.
Read more →DRIODarioHealth Announces CFO Transition
DarioHealth Corp. announced the upcoming retirement of CFO Zvi Ben-David, effective May 15, 2025. The company has appointed Chen Franco-Yehuda, who has a strong background in financial leadership, as the new CFO. Ben-David will assist the company in an advisory capacity until the end of June. The leadership transition is expected to support DarioHealth's strategic growth and innovation.
Read more →DRIODarioHealth Collaborates with Leading National Benefit Plan Administrator to Offer Cardiometabolic Solution including a GLP-1 Support Program to Employers
DarioHealth Corp. has announced a strategic partnership with a leading national benefit administrator to provide its comprehensive cardiometabolic solution, including a GLP-1 support program, to employers. This collaboration aims to address healthcare costs associated with metabolic conditions and is viewed as a significant step toward wider adoption of Dario's digital health solutions. Initial implementations have already started contributing to the company’s revenues in the first quarter of 2025, reflecting the potential for growth in this sector. The partnership underscores Dario's commitment to managing chronic conditions while facilitating access to effective therapies.
Read more →DRIOTop U.S. Healthcare Institution Deploys DarioHealth
DarioHealth Corp. has secured a new partnership with a leading U.S. healthcare institution, enhancing its presence in the digital health market. This agreement, aimed at improving chronic condition management, is already live and generating recurring revenue for 2025. The collaboration underscores DarioHealth's commitment to providing personalized, data-driven health solutions integrated into a user-friendly platform. As digital health adoption expands, this partnership may solidify DarioHealth's reputation as a trustworthy provider in the sector.
Read more →DRIODarioHealth Announces New Agreement with a Large Regional Health Plan
DarioHealth Corp. has secured a new agreement with a large regional health plan, enhancing its presence in the payer market. The program, initiated in January 2025, enables members access to Dario's AI-driven health coaching tools. This partnership is expected to contribute positively to Dario's annual recurring revenue and may expand to include a broader member population over the coming year. With this expansion, DarioHealth continues to strengthen its role in the rapidly growing cardiometabolic care sector.
Read more →DRIODarioHealth Reports Fourth Quarter and Full year 2024 Financial and Operating Results
DarioHealth Corp. (NASDAQ: DRIO) announced its financial results for Q4 and the full year 2024, showcasing a strong revenue increase of 32.9% to $27.0 million. The growth was significantly driven by the B2B2C channel, with recurring revenues soaring by 300%. Dario aims to reach an operational cash flow breakeven by the end of 2025, fueled by ongoing cost management strategies and a successful integration of its recent acquisition, Twill Inc. The company also added 36 new clients, expanding its total to 83, while maintaining high client renewal rates.
Read more →DRIODario Expands Behavioral Health Offerings to Include a Provider Network Through Strategic Arrangement with Rula
DarioHealth Corp. announced a strategic collaboration with Rula Health to enhance access to behavioral health services for employers and their workforce. This partnership provides access to an extensive network of over 15,000 providers, enabling a more comprehensive and effective mental health solution. The collaboration aims to accelerate Dario's sales growth in the B2B2C channel and improve visibility within Rula's partner base. Dario's digital platform, combined with Rula's provider network, strives to deliver integrated mental health support tailored to unique health journeys.
Read more →DRIODario Signs First Healthcare System as Employer Contract, Expanding Market Presence and Recurring Revenue Growth
DarioHealth Corp. has secured its first contract with a major healthcare system, set to implement AI-powered chronic care management solutions for its healthcare worker employees in early 2025. This partnership is aimed at enhancing care delivery for chronic conditions like diabetes and hypertension, marking a key expansion in Dario's employer client base. The agreement showcases growing confidence in digital health solutions among healthcare providers, aligning with Dario's goals for client acquisition and improved health outcomes.
Read more →DRIODarioHealth to Report Fourth Quarter and Full Year 2024 Results on Monday, March 10, 2025
DarioHealth Corp. is set to announce its financial results for the fourth quarter and full year of 2024 on March 10, 2025. The conference call will take place at 8:30 am Eastern Time, featuring remarks from CEO Erez Raphael and CCO Steven Nelson. The company specializes in digital health platforms aimed at improving the management of chronic conditions through personalized interventions. This announcement highlights DarioHealth's commitment to engaging with investors and stakeholders.
Read more →DRIODarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platfor
DarioHealth Corp. has appointed Larry Leisure, a seasoned professional with extensive experience in healthcare and digital health, to its Board of Directors. Leisure's background includes leadership roles at Accenture, Kaiser Foundation, and UnitedHealth Group, which positions him to advance Dario's AI-driven chronic care platform. His insights are expected to enhance Dario's expansion within payer and employer markets, contributing to improved health outcomes through innovative solutions.
Read more →DRIODarioHealth Announces $25.6M Private Placement Positioning the Company to Execute on Strategy Aiming to Reach Operational Cash Flow Positive Run Rate by the End of 2025 Significant participation from existing shareholder
DarioHealth Corp. announced the completion of a $25.6 million private placement of convertible preferred stock, primarily funded by existing shareholders. This financing aims to enhance the company's financial stability and support its strategy to achieve an operational cash flow positive run rate by the end of 2025. The funds are expected to extend Dario's cash runway, facilitating continued growth in high-margin, recurring revenue streams across B2B and pharmaceutical channels. CEO Erez Raphael emphasized the positive shareholder confidence demonstrated through their participation in this offering.
Read more →DRIODarioHealth Expands GLP-1 Solution with Prescribing Capabilities through Collaboration with MediOrbis, Targeting Employers and Direct-to-Consumer Markets
DarioHealth Corp. has announced a collaboration with MediOrbis, aimed at enhancing its GLP-1 weight-loss solution by incorporating virtual physician prescribing capabilities. This strategic move is designed to meet the increasing demand from employers for comprehensive weight management programs. As the market for GLP-1 medications continues to grow, DarioHealth seeks to improve health outcomes and return on investment for employers while facilitating seamless care paths for users. The collaboration positions DarioHealth for potential growth in both employer and direct-to-consumer markets.
Read more →DRIODario Signs Four New Employer Contracts Across Full Product Suite
DarioHealth Corp. has signed four new contracts with self-insured employers, anticipated to commence in the first quarter of 2025. This initiative is part of their business-to-business-to-consumer growth strategy, which aims to enhance recurring revenue and increase client base by approximately 35% in 2024 compared to 2023. The contracts will utilize Dario's entire suite of digital health solutions, emphasizing the value of comprehensive care offerings. According to Dario's Chief Commercial Officer, the growth in employer contracts is expected to significantly contribute to the company's profitability timeline.
Read more →DRIODarioHealth Reports Third Quarter 2024 Financial and Operating Results
DarioHealth Corp. (Nasdaq: DRIO) reported strong financial results for Q3 2024, with revenues reaching $7.42 million, reflecting an 111% increase from the previous year. The company noted a significant reduction in operating losses and credited its success to the expansion of its B2B2C revenue model and the synergies from its merger with Twill. With the addition of ten new clients, including a national Medicare health plan, Dario is strategically positioned for sustained growth heading into 2025. The CEO expressed optimism about achieving profitability and enhancing their service offerings through technology integration.
Read more →DRIODario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement
DarioHealth Corp. has announced a significant collaboration with a prominent U.S. pharmaceutical company to utilize its Dario Connect platform for enhancing patient engagement with a new psoriasis treatment. This partnership marks a pivotal shift to a subscription-based revenue model, moving away from milestone payments. The initiative aims to onboard patients and gather insights into treatment effectiveness, leveraging Dario's community-building capabilities. The collaboration will also enable better data integration for healthcare providers and pharmaceutical companies, promoting comprehensive patient care.
Read more →DRIODario Signs New Regional Health Plan, Expanding Reach in Medicaid Population
DarioHealth Corp. has secured a new contract with a regional Medicaid health plan, marking it as their eighth health plan partnership. This agreement is expected to deliver immediate revenue impact and highlights Dario's successful engagement strategies for diverse populations. The company aims to utilize this partnership to address engagement challenges within the Medicaid demographic while planning further expansion in this segment by 2025.
Read more →DRIODarioHealth to Report Third Quarter 2024 Results on Thursday, November 7th
DarioHealth Corp. (NASDAQ: DRIO) has announced that it will release its financial results for the third quarter of 2024 on November 7th. Along with the results, the company will host a conference call at 8:30 AM ET, which will include insights from CEO Erez Raphael and CCO Steven Nelson. The call can be accessed through various means, including a dedicated webcast. DarioHealth continues to focus on transforming chronic condition management through its digital therapeutics platform.
Read more →DRIODario Announces Complete Integration of Twill Capabilities Across Full Multi-Condition Platform
DarioHealth Corp. has announced the full integration of Twill's behavioral health and navigation capabilities into its platform, creating a more comprehensive digital health solution. This integration allows Dario to offer an end-to-end approach that addresses both mental and physical health for chronic condition management. The platform now supports multiple health conditions and enhances user engagement through personalized care pathways. Dario aims to revolutionize the digital health landscape by improving access and outcomes for its members.
Read more →DRIOTwill by Dario to Offer a Benefit for AARP Members
DarioHealth Corp. (Nasdaq: DRIO) announced a new member benefit for AARP members that will provide access to its digital behavioral health platform, Twill by Dario, starting January 2025. This initiative aims to address the growing mental health needs among individuals over 50, such as loneliness and anxiety. The platform offers tailored solutions and easy access to health support, empowering users to manage their wellbeing effectively. DarioHealth’s collaboration with AARP signifies a strategic move to enhance its market presence and fulfill its commitment to improving digital health solutions for older adults.
Read more →DRIONational Medicare Health Plan Partners with Twill by Dario to Promote Healthy Aging with New Digital Mental Health Benefits for Seniors
DarioHealth Corp. has announced a new contract with a national Medicare Advantage health plan to launch its behavioral health solution, Twill by Dario, starting January 2025. This contract will significantly increase Dario's revenue potential and is aimed at promoting healthy aging for seniors through integrated digital mental health benefits. With this partnership, Dario aims to address seniors' emotional health needs and has plans for future expansions to include additional solutions. This marks an important milestone as it is the first national health plan contract in the Medicare Advantage market for Dario.
Read more →DRIODario Introduces Integration of Twill Behavioral Health Capabilities into Cardiometabolic Health Solution to Enhance Member Engagement and Outcomes
DarioHealth Corp. has announced the integration of Twill's behavioral health capabilities into its cardiometabolic health solution, aimed at enhancing member engagement and improving health outcomes. This new feature allows members to join peer groups and access personalized content to support their health management journey. The integration represents a significant advancement in Dario's digital health offerings, combining social support with chronic condition management. Dario's leaders emphasize the importance of continuous assessment to optimize user engagement and effectiveness of their platform.
Read more →DRIODario Publishes New Research Revealing How Physical Activity Mediates the Impact of Depression on Blood Glucose Levels in Individuals with Diabetes or Prediabetes
DarioHealth Corp. has published new research in the journal Frontiers in Endocrinology, highlighting the effectiveness of its cardiometabolic solution for individuals living with type 2 diabetes or prediabetes and depression. The study indicates that a holistic approach, which includes mental health support and physical activity tracking, significantly improves blood glucose levels. Specifically, regular walking was found to mediate the negative impact of depression on glycemic control. This research underscores the value of integrated data in enhancing patient health outcomes.
Read more →DRIODarioHealth Reports Second Quarter 2024 Financial and Operating Results
DarioHealth Corp. reported its Q2 2024 financial results, highlighting a revenue increase driven by growth in the B2B2C channel. The company witnessed a 315% surge in recurring revenues, significantly aided by the recent acquisition of Twill. DarioHealth anticipates a substantial decrease in operating losses over the next year due to aggressive cost-cutting measures and expanding revenue streams. Furthermore, the company aims to achieve cash flow breakeven by the end of 2025, supported by increased client adoption of its GLP-1 products and a strategic transition to a more stable revenue model.
Read more →DRIODarioHealth to Report Second Quarter 2024 Results on Thursday, August 8th
DarioHealth Corp. will announce its financial results for the second quarter of 2024 on August 8th. The announcement includes a scheduled conference call for stakeholders to discuss the results, which will be hosted by CEO Erez Raphael and CCO Steven Nelson. DarioHealth is noted for its innovative digital therapeutics platform that assists patients with chronic health conditions. The anticipation around their earnings report indicates strong interest from investors and the market.
Read more →DRIODario Expands GLP-1 Solution Client Base with New Employer Contract
DarioHealth Corp. (NASDAQ: DRIO) has secured a new contract with a national employer to provide its cardiometabolic solution that includes integrated support for GLP-1 medications, set to begin in the third quarter of 2024. This partnership aims to help employees manage various health conditions, such as diabetes and hypertension, while enhancing engagement through data-driven personal support. The integration of Twill's capabilities further boosts Dario's ability to facilitate sustainable behavior change, which is crucial for successful medication adherence. Dario anticipates that several more employers will soon adopt their integrated health solutions.
Read more →DRIODario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1
DarioHealth Corp. announced positive findings from two studies concerning the effectiveness of its digital health platform in promoting sustained healthy behavior changes among users taking GLP-1 medications. The research showed that members successfully maintained healthy behaviors for 12 months and noted that 31% of individuals with Type 2 diabetes achieved diabetes remission. Dario's platform demonstrated increased tracking of lifestyle activities and significant improvements in blood glucose levels over time. These results suggest that Dario's approach may enhance the efficacy of GLP-1 treatments in managing diabetes.
Read more →DRIOEmpowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer
DarioHealth Corp. has announced a strategic reorganization to enhance its commercial operations, culminating in the appointment of Steven Nelson as the inaugural Chief Commercial Officer. This restructuring aims to streamline leadership by eliminating the President role while establishing dedicated C-level positions for core functions. Nelson brings over two decades of healthcare experience, with a focus on scaling revenue and improving market strategies. The company believes these changes will accelerate commercialization efforts, ensuring a greater impact as it seeks to capitalize on its expanded product pipeline.
Read more →DRIODarioHealth Reports First Quarter 2024 Financial and Operating Results
DarioHealth Corp. reported a revenue increase of 59% for Q1 2024 compared to the previous quarter, primarily driven by growth in its B2B2C revenue channel, which accounted for 60% of total revenues. However, total revenue declined by 18.5% year-over-year due to milestone-driven revenues. The acquisition of Twill Inc. has significantly enhanced Dario's revenue mix and market position. The company expects to reach breakeven by the second half of 2025, supported by anticipated strong growth in its core business and operational efficiencies.
Read more →DRIODarioHealth to Report First Quarter 2024 Results on Wednesday, May 15th
DarioHealth Corp. (Nasdaq: DRIO) announced that it will release its first quarter 2024 financial results on May 15th, 2024, prior to market opening. A conference call and webcast will follow at 8:30 am ET, hosted by CEO Erez Raphael and President Rick Anderson. Participants are encouraged to join the event approximately 10 minutes early, and a replay will be available after the call for those unable to attend live. DarioHealth continues to focus on digital therapeutics solutions for chronic condition management.
Read more →DRIODario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes
DarioHealth Corp. has published a new peer-reviewed study in the Journal of Internet Medicine, demonstrating that its integrated digital health platform significantly improves clinical outcomes for patients managing diabetes and weight. The quasi-randomized study involved 1,932 members and found that those using the weight monitoring feature had a substantial reduction in blood glucose levels compared to those who did not. Eighty-five percent of those utilizing weight management achieved blood glucose levels below the estimated A1c threshold, indicating the effectiveness of Dario's combined approach. This research supports the growing evidence for the benefits of integrated chronic condition management solutions.
Read more →DRIODario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution
DarioHealth Corp. has announced new contracts to provide its integrated cardiometabolic management solutions to two employers, aiming to improve the health outcomes of employees with related conditions. The solutions will support conditions such as diabetes and hypertension, particularly for individuals on GLP-1 medications. This move reflects the growing demand for cohesive health management solutions that reduce reliance on multiple point solutions. Dario's approach combines advanced technology with personalized experiences to enhance member engagement and satisfaction.
Read more →DRIODario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health
DarioHealth Corp. has released two new studies published in the Journal of Internet Medicine, showcasing the effectiveness of their digital health interventions. A randomized controlled trial revealed significant improvements in perceived stress and loneliness among teens using a self-guided digital mental health intervention. Another study demonstrated the efficacy of digital tools like breathing exercises and CBT-based videos in reducing stress over a 10-week period. The company aims to provide accessible mental health support, particularly for those without access to in-person resources.
Read more →DRIOTwo National Employers Select Dario
DarioHealth Corp. has secured contracts with two national employers to provide integrated solutions for chronic condition management starting in Q2 2024. The first employer, a global investment group, will utilize Dario's cardiometabolic suite to enhance health outcomes for employees dealing with conditions like diabetes and hypertension. The second employer, a national professional services firm, aims to deliver personalized support across various health needs, including musculoskeletal and behavioral health. Dario's offerings emphasize a user-centric approach that combines technology and data insights.
Read more →DRIODarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results
DarioHealth Corp. reported its financial and operational results for the fourth quarter and full-year 2023, highlighting a shift towards a B2B2C model. Total revenues for 2023 amounted to $20.4 million, a decrease compared to 2022, mainly due to lower B2C sales. However, revenues from B2B2C agreements grew significantly, reflecting the company's strategic focus. The acquisition of Twill is anticipated to enhance revenue potential and efficiency, aiming for profitability by 2025. DarioHealth concluded the year with a strong cash position and expressed optimism for growth in upcoming quarters.
Read more →DRIODARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28TH
DarioHealth Corp. (Nasdaq: DRIO) has announced the forthcoming release of its financial results for the fourth quarter ending December 31, 2023. The financial disclosures are scheduled for March 28, 2024, before market opening, followed by a conference call at 8:30 am ET. The company continues to highlight its leading position in the digital therapeutics market, focusing on personalized care for chronic health conditions.
Read more →DRIONew Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications
DarioHealth Corp. presented two new clinical studies at the ATTD 2024 conference, highlighting the effectiveness of their integrated cardiometabolic solution. The first study showed that members using Dario's digital platform experienced significant weight loss and controlled blood glucose levels, particularly for those engaged in meal tracking activities. The second study indicated improved flu vaccine awareness and uptake among members with diabetes, demonstrating the potential of digital health platforms to enhance health outcomes. These findings support Dario's commitment to delivering personalized, effective interventions for chronic conditions.
Read more →DRIODARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE
DarioHealth Corp. will participate in the Cowen 44th Annual Healthcare Conference from March 4-6, 2024, in Boston, Massachusetts. CEO Erez Raphael and President Rick Anderson are scheduled to engage in a fireside chat on March 6th. The event will be accessible via a live webcast and will be available for replay for 90 days afterward. DarioHealth focuses on transforming health management for individuals with chronic conditions through its user-centric digital therapeutics platform.
Read more →DRIOA Comprehensive, User-Centric Digital Health Platform DarioHealth Corp. + Feb 21st, 2024 2 01 This presentation of DarioHealth Corp. (“Dario”, the “Company”, “we” and “our
DarioHealth Corp. reported a significant improvement in its financial metrics, showcasing a growth trajectory in revenue and gross margins. The company anticipates gross margins may reach 80-85% as they scale operations. There is a noted decrease in operating expenses, attributed to various factors including the ramp down of direct-to-consumer (B2C) efforts and M&A consolidation. Additionally, strong revenue contributions from both B2B2C ventures and strategic partnerships highlight Dario's expanding market presence.
Read more →DRIODario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditions
DarioHealth Corp. has announced the acquisition of Twill, aiming to create a comprehensive digital health platform targeting chronic conditions. The acquisition is projected to nearly double Dario's pro forma revenue for 2023 and enhance gross margins. Concurrently, Dario is executing a $22.4 million equity financing. The integration of Twill's offerings is expected to accelerate Dario's profitability path and expand engagement capabilities.
Read more →DRIORegional Union Selects Dario
DarioHealth Corp. has secured a new contract to provide its cardiometabolic solution to a regional union representing food industry workers, set to start in Q1 2024. This contract will deliver support for employees managing diabetes and weight management, as well as those on anti-obesity medications. Dario's integrated approach has been recognized for its effectiveness, and the company sees this contract as an indicator of strong demand in 2024, following similar previous contracts. The company emphasizes its proven results in engaging users and improving health outcomes.
Read more →DRIONational Employer Selects Dario Cardiometabolic and GLP-1 Solutions to Improve Employee Health
DarioHealth Corp. has announced a new contract with a national logistics company to provide cardiometabolic and GLP-1 health solutions starting January 2024. The integrated support will target employees managing diabetes, pre-diabetes, and hypertension, alongside those on GLP-1 medication. Dario's platform utilizes intelligent technologies and expertise to promote long-term behavior changes, aiming to enhance health outcomes for the employer's workforce. This initiative is part of Dario's broader mission to revolutionize chronic condition management through personalized digital health solutions.
Read more →DRIODario Contracts with New Employer for Cardiometabolic Solution
DarioHealth Corp. announced a new contract with a national financial services employer to provide its integrated cardiometabolic solution beginning January 2024. This solution aims to enhance the health of employees dealing with diabetes, weight management, and hypertension, especially those using GLP-1 medications. Dario leverages its decade-long experience to deliver personalized health experiences and has a track record of achieving positive clinical outcomes. The contract reflects growing interest in effective digital health approaches for chronic condition management.
Read more →DRIONew Research Sheds Light on Mediators of Improved Outcomes in Dario Users
DarioHealth Corp. announced new analyses presented by Sanofi U.S. highlighting improved clinical and economic outcomes for users of its digital health solution. The studies, showcased at recent conferences, found that Dario users experienced significant reductions in HbA1c and improved medication adherence. Additionally, more engaged users reported reduced healthcare resource usage and costs. This research enhances Dario's credibility in the digital health space and reflects the effectiveness of their personalized solutions.
Read more →DRIODario Publishes New Research Demonstrating that Dario Users That Increased Physical Activity Can Maintain Reduced Blood Glucose
DarioHealth Corp. announced new research at the Diabetes Technology Society 2023 Meeting that highlights the effectiveness of combining physical activity tracking with blood sugar monitoring for individuals with diabetes and pre-diabetes. The study revealed significantly reduced blood glucose levels and increased physical activity among Dario users over a 12-month period. By integrating clinical and behavioral data within its digital health platform, Dario aims to enhance the management of chronic health conditions, particularly for users taking GLP-1 medications. This research underscores the potential benefits of a holistic health approach in improving patient outcomes.
Read more →DRIODarioHealth Reports Third Quarter 2023 Financial and Operating Results
DarioHealth has reported its Q3 2023 financial results, showing a total revenue of $3.52 million, down from $6.6 million in the same quarter last year. However, the company experienced a 19.3% increase in B2B2C revenue, supported by an anticipated growth in partnerships and new customers. Dario's relationship with Aetna was expanded, expected to generate over $1 million in annual recurring revenues starting Q1 2024. Despite the decrease in total revenue, the company maintains a strong financial position with cash reserves of $44 million.
Read more →DRIODario Launches Apple iPhone 15 Accessible Smart Blood Glucose Meter
DarioHealth Corp. has launched a new smart blood glucose meter designed for Apple iPhone 15 users. This device utilizes the new USB-C charging port to provide real-time blood sugar readings, enhancing user engagement with Dario's health management platform. Company President Rick Anderson stated that the innovation demonstrates Dario's commitment to responding to consumer needs. The smart meter is part of Dario's broader digital health solutions aimed at managing various chronic conditions.
Read more →DRIODarioHealth to Report Third Quarter 2023 Results on Thursday, November 2nd
DarioHealth Corp. (Nasdaq: DRIO) is set to release its third quarter 2023 financial results on November 2, 2023, before market opens. The company will host a conference call at 8:30 AM ET to discuss these results, led by CEO Erez Raphael and President Rick Anderson. DarioHealth specializes in digital health solutions that enable better management of chronic conditions through a multifaceted therapeutic approach.
Read more →DRIONew Research Shows 36% Reduction in 30-Day Hospital Readmission Rate for Dario Users with Type 2 Diabetes
DarioHealth Corp. announced new research demonstrating a 36% reduction in 30-day hospital readmission rates for users of its digital health solutions for type 2 diabetes. Presented by Sanofi U.S. at the AMCP-Nexus conference, the study highlights the significant reduction in healthcare costs associated with Dario's application. The research earned a gold ribbon award, affirming the success of Dario's user-centric platform and its effectiveness in improving patient outcomes. Additional analyses indicated enhancements in HEDIS measurements for diabetes management.
Read more →DRIOInvestors Day DarioHealth Corp. Nasdaq | DRIO | October 17th, 2023 01 This presentation of DarioHealth Corp. (“Dario”, the “Company”, “we” and “our”) and statements
DarioHealth Corp. showcased significant financial metrics during its recent Investors Day, highlighting a continuous improvement in gross margins, now at 57% for the first half of 2023. The company reported a successful reduction in operating expenses, with expectations for this trend to continue into 2024, primarily due to B2C ramp down and strategic consolidation measures. Additionally, DarioHealth's B2B2C business is achieving notable cash flow positive results, which should support its long-term growth strategy. Strategic partnerships, particularly with companies like Sanofi and Aetna, are anticipated to bolster commercial advancements and revenue streams.
Read more →DRIODario Signs National Preferred Partner Agreement with a Top Five National Employee Benefits Consulting Firm
DarioHealth Corp. has entered a strategic partnership with a top five national employee benefits consulting firm, becoming its preferred digital health provider. This agreement allows the firm’s consultants to offer Dario’s chronic condition management solutions, which include options for diabetes, hypertension, and behavioral health. The partnership aims to deliver improved health outcomes and lower costs for employer clients leveraging Dario's innovative digital therapeutics platform. Dario's user-centric approach emphasizes sustained engagement and personalized care.
Read more →DRIODarioHealth to Host Investor Day on The Rise of Digital Health
DarioHealth Corp. has announced an upcoming in-person investor day scheduled for October 17, 2023, in New York. The event will feature discussions led by prominent figures in the digital health industry, addressing the growing importance of digital health technologies. Participants will learn about Dario's innovative platform designed for chronic condition management and hear from clients using the platform to improve health outcomes. The company's executive team will delve into product growth strategies and engage with attendees through a Q&A session.
Read more →DRIODario Publishes New Research Demonstrating Clinically Significant Reductions in Depression Through its Digital Behavioral Health Programs
DarioHealth Corp. published new research indicating that 63% of users of its digital behavioral health program experienced significant reductions in depression and anxiety symptoms. The study, published in the Journal of Medical Internet Research, focused on the effectiveness of coaching and breathing exercises utilized over a 16-week period in managing mental health. Participants in the program benefited from a personalized approach, with self-guided methods supported by coaches or digital tools. This research underscores the potential for digital health solutions to improve mental health outcomes among users through tailored support.
Read more →DRIODario Publishes New Research Demonstrating Greater Engagemenet and Improved Clinical Outcomes Sustainable for Two Years
DarioHealth Corp. announced new research at the ADCES23 Annual Conference, revealing that its digital health solutions significantly enhance health outcomes for diabetes patients. Analysis of data from 119,482 members indicated a 29% increase in engagement over two years, correlating with improved glucose metrics for users at high risk of diabetes. Company executives emphasized that their digital platform is designed to sustainably improve health outcomes through behavior changes.
Read more →DRIODario Partners with PlanSource to Offer Employers Easy Access to Proven Digital Health Solutions
DarioHealth Corp. has entered into a partnership with PlanSource to provide integrated digital health solutions aimed at employers and their employees. The new agreement enables easy access to Dario's chronic condition management tools for over 5 million consumers, enhancing the employer's health benefit plans. Dario's solutions target various health issues, leveraging data analytics to optimize both digital and human support in managing chronic conditions. The collaboration is expected to improve access and enhance health outcomes, even amidst challenges in the healthcare economy.
Read more →DRIODarioHealth Reports Second Quarter 2023 Financial and Operating Results
DarioHealth Corp. reported its financial results for the second quarter of 2023, highlighting revenue growth from B2B channels and an improved gross profit margin. Despite a slight decrease in total revenues compared to the same quarter of the previous year, the company successfully reduced operating expenses and launched new solutions in partnership with various health plans. DarioHealth holds a strong financial position with $52.6 million in cash as of the quarter's end, supporting its operations through at least 2025. A focus on expanding B2B opportunities is expected to drive growth moving forward.
Read more →DRIODario Expands Partnership with Large Regional Health Plan
DarioHealth Corp. has announced the expansion of its partnership with a regional health plan to provide personalized digital health solutions for diabetes. The launch is expected in the first quarter of 2024, complementing current hypertension support. This move aligns with Dario's multi-condition strategy and demonstrates the company's ability to drive demand among payers while offering significant cost savings for users. Dario's platform aims to enhance engagement and improve health outcomes for members managing chronic conditions.
Read more →DRIODarioHealth to Report Second Quarter 2023 Results on Thursday, August 10th
DarioHealth Corp. will release its financial results for the second quarter of 2023 on August 10. The company will host a conference call and webcast at 8:30 a.m. ET, led by CEO Erez Raphael and President Rick Anderson. This event aims to update stakeholders on the company's performance, underlining DarioHealth's ongoing presence in the digital health market.
Read more →DRIODario Introduces GLP-1 Behavior Change Program to Help Achieve Weight Loss Goals and Better Overall Health Outcomes
DarioHealth Corp. has launched a new behavior change program designed for individuals using GLP-1 medications aimed at achieving weight loss and enhancing overall health outcomes. This initiative integrates personalized coaching and a digital Medication Cabinet to track adherence to prescribed treatments. The company acknowledges challenges such as the high discontinuation rate of GLP-1s within the first year and highlights its commitment to providing data-driven insights to its partners. The program focuses on driving sustainable behavioral changes through a comprehensive approach that combines technology with human support.
Read more →DRIONew Research Shows $5,077 in Medical Costs Savings for Dario Users
DarioHealth Corp. announced findings from a new study demonstrating a substantial $5,077 reduction in medical costs for users of its digital health solutions compared to non-users with Type 2 diabetes. The retrospective cohort study, presented at the American Diabetes Association 83rd Scientific Sessions, analyzed healthcare claims over a year, showing enhanced care efficiency and reduced hospitalizations for users. This collaborative research with Sanofi US aims to set new standards for evidence-based digital health initiatives, highlighting the economic benefits of Dario's platform.
Read more →DRIODario Launches Agreement with Large Regional Health Plan and Announces Preliminary Results for Second Quarter of 2023 as well as Business Update New account is set to launch in July 2023 for eligible members New York, N.
DarioHealth Corp. announced a new agreement with a significant regional health plan to provide digital health solutions for more than 160,000 members with hypertension. The company reported preliminary second-quarter revenue results of between $6.0 million and $6.15 million, largely influenced by growth in Business-to-Business sales. However, revenue from strategic partnerships fell short of expectations due to fewer milestone deliveries. DarioHealth is optimistic about future revenue contributions from recent contracts with key partners.
Read more →DRIODario Announces New Full Suite Employer Contract
DarioHealth Corp. has announced a new employer contract that will launch in the second half of 2023, potentially contributing to the company's revenue. The contract is with an educational organization in the Midwest, providing a suite of digital health solutions for various chronic conditions. This development reflects growing demand among employers for integrated healthcare solutions amidst rising chronic condition management costs. Dario anticipates that its proven capabilities in reducing costs and improving clinical outcomes will offer compelling value to this new client.
Read more →DRIONew Research Demonstrates 2.3 Point Reduction in HbA1c for Dario Digital Health Users with Baseline HbA1c Greater Than 9 points
DarioHealth Corp. presented new research at the American Diabetes Association 83rd Scientific Sessions, revealing that users of its digital health platform achieved a 2.3 point reduction in HbA1c, compared to a 1.8 point reduction for non-users. The study was conducted in collaboration with Sanofi and analyzed real-world data for a cohort of 568 Dario users versus 1,699 matched controls. This research showcases clinically significant reductions tailored to users with serious diabetes, setting a higher standard for digital health interventions and evidence generation.
Read more →DRIODario Announces Two New Full Suite Employer Contracts
DarioHealth Corp. has announced the acquisition of two new employer contracts for its integrated digital health solutions, expected to launch in the second half of 2023. The contracts include an educational organization in Tennessee and a non-profit in the New York metropolitan area. DarioHealth's platform aims to deliver efficient management of chronic health conditions, helping employers manage costs and streamline care for employees. This move reflects a growing demand for comprehensive health solutions among employers.
Read more →DRIODario Management to Participate in the Stifel 2023 Virtual Cross Sector Insight Conference
DarioHealth Corp. will participate in the Stifel 2023 Virtual Cross Sector Insight Conference on June 6-7, 2023. President Rick Anderson is scheduled to present on June 6 at 4:45 PM EST. The conference aims to showcase insights across various sectors, providing Dario an opportunity to highlight its digital health solutions. These solutions focus on chronic condition management through personalized and data-driven interventions.
Read more →DRIOMedOne Launches Dario
DarioHealth Corp. has partnered with MedOne Pharmacy Benefit Solutions to integrate its digital health solutions into MedOne's Diabetes Care Path program. This collaboration aims to enhance support for diabetic patients and improve health outcomes while optimizing treatment plans. The phased rollout of Dario's solutions will begin immediately, allowing current MedOne members access to new digital health offerings starting June 1, 2023. This partnership is a culmination of Dario's strategic collaboration with Sanofi US, which was announced previously, marking a significant milestone in their mutual efforts to enhance chronic condition management.
Read more →DRIODarioHealth Reports First Quarter Financial and Operating Results
DarioHealth Corp. reported its financial results for the first quarter of 2023, highlighting sequential revenue growth to $7.07 million and improvements in gross profit margins. The company successfully signed strategic partnerships with Amwell and Sanofi, enhancing its market position. However, revenue declined 12.3% from the same quarter last year, primarily due to underperformance in its Business-to-Consumer channel. Despite some challenges, net loss reduced to $12.8 million compared to $15.9 million in Q1 2022, signaling ongoing efforts to enhance financial stability.
Read more →DRIOSanofi research demonstrates 9.3% reduction in all-cause healthcare resource utilization rates, including 23.5% decrease in hospitalization for Dario users
DarioHealth Corp. presented compelling research at ISPOR 2023, showing a 9.3% reduction in healthcare resource utilization for users of its digital diabetes solution. The study, conducted in partnership with Sanofi U.S., highlighted a 23.5% decrease in hospitalizations after a year of usage. This marks a significant advance in demonstrating the effectiveness of digital health solutions in chronic disease management, fostering a holistic approach to health care. The research lays the groundwork for future studies assessing the impact of Dario's offerings on health outcomes and cost savings.
Read more →DRIODarioHealth to Report First Quarter 2023 Results on Thursday, May 11th
DarioHealth Corp. (Nasdaq: DRIO) announced it will release its first-quarter financial results for 2023 on May 11, before the market opens. A conference call and webcast will be hosted at 8:30 AM ET, featuring CEO Erez Raphael and other executives. The company is known for its innovative digital health solutions aimed at managing chronic conditions. The results will provide insights into the company's performance and strategic direction.
Read more →DRIODarioHealth Announces $14.3 Million Private Placement Newly designated convertible preferred stock priced at the market under Nasdaq rules with significant participation by select members of leadership, the Board and exi
DarioHealth Corp. announced a successful $14.3 million private placement of convertible preferred stock, priced in line with Nasdaq regulations. This funding will provide significant support through an extended cash runway until late 2025. Additionally, the company has refinanced its existing $25 million credit facility, resulting in notable savings on amortization payments. The announcement was well-received, with participation from leadership and the board, reflecting high confidence in the company's growth strategy.
Read more →DRIODigital Health Product Leader, Eitan Shay, Joins Dario as Chief Product Officer
DarioHealth Corp. has announced the appointment of Eitan Shay as Chief Product Officer and Arnaud Robert as Strategic Advisor to the CEO. These appointments are expected to enhance Dario's ability to scale its digital therapeutics platform, which is experiencing increasing demand from payers and employers. Shay brings significant experience from previous roles at Livongo and Teladoc, while Robert's background includes leadership at Sanofi, Nike, and Disney. This strategic move is part of Dario's growth strategy aimed at accelerating innovation and improving consumer engagement.
Read more →DRIODario Selected as Digital Therapeutics Partner by a Top-Ten Digitally Enabled Pharmacy Benefits Manager
DarioHealth Corp. has entered into a new contract with a leading Pharmacy Benefits Manager to provide its digital diabetes solution. This agreement is part of a strategic partnership with Sanofi U.S. and is expected to generate revenue starting in the second quarter of 2023. The new contract showcases Dario's strong market position as it transitions existing users from another digital diabetes offering. The collaboration is viewed as a critical step in expanding Dario's solutions within the healthcare market.
Read more →DRIODario Announces Strategic Partnership with Amwell to Expand Access to its Cardiometabolic Digital Therapeutic Solution
DarioHealth Corp. has announced a strategic partnership with Amwell to integrate its cardiometabolic digital therapeutic solution into Amwell's digital care delivery platform, which serves over 90 million lives. This collaboration aims to enhance the management of chronic conditions like diabetes and hypertension for Amwell's clients. Dario's solutions will be directly available through Amwell's platform beginning in the second half of 2023. The partnership is seen as a move to fulfill the increasing demand for more comprehensive healthcare solutions while reducing costs for buyers.
Read more →DRIODario Publishes New Research Demonstrating Digital Personalization of Pain Management with Adapted Machine Learning
DarioHealth Corp. has published new research in Pain Reports highlighting the effectiveness of its digital therapeutics for pain management. The study focused on personalized user experiences using machine learning within their posture training program, revealing significant reductions in back pain for users over three weeks. Conducted in partnership with the University of Haifa, the research emphasizes the importance of adapting solutions to individual needs, thereby optimizing user care and outcomes. Dario's approach aims at transforming pain management through innovative, data-driven strategies.
Read more →DRIODarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating Results
DarioHealth reported strong financial results for the fourth quarter and full year 2022, with revenues rising to $27.7 million, a 34.8% increase from the previous year. The company's successful pivot to a Business-to-Business model has significantly improved gross margins and reduced operating losses. Ending the year with cash reserves of $49.3 million, DarioHealth is positioned for continued growth, particularly with the establishment of 100 B2B contracts and partnerships that could amplify revenue. The CEO expressed optimism for 2023, highlighting the potential for expanded market presence and improved customer acquisition efficiency.
Read more →DRIODarioHealth to Report Fourth Quarter 2022 Results on Thursday, March 9th
DarioHealth Corp. announced it will release its financial results for the fourth quarter and year ended December 31, 2022, on March 9, 2023. The company will host a conference call and webcast at 8:30 AM ET, featuring leadership from DarioHealth. This event will provide insights into the company's performance and future outlook in the digital therapeutics space.
Read more →DRIONew Research from Dario Demonstrates Improved Clinical Outcomes in Two New Studies at the Advanced Technologies and Treatments for Diabetes 2023 Conference
DarioHealth Corp. presented two clinical studies at the ATTD 2023 conference, demonstrating improvements in clinical outcomes for diabetes management. One study showed a significant reduction in blood glucose levels among Type 2 diabetes users who engaged with coaching compared to those who did not. The second study highlighted the effectiveness of Dario's digital solutions in reducing hypoglycemic events among older adults. These findings support the potential of combining human coaching with digital interventions to enhance patient outcomes.
Read more →DRIODarioHealth to Participate in the Cowen 43rd Annual Healthcare Conference
DarioHealth Corp. (Nasdaq: DRIO) announced its participation in the Cowen 43rd Annual Healthcare Conference scheduled for March 6-8, 2023. The company's CEO Erez Raphael and President Rick Anderson will engage in a fireside chat during the event. DarioHealth is recognized for its comprehensive digital therapeutic solutions addressing various chronic conditions. A live webcast of the event will be available on their investor relations website.
Read more →DRIODario Appoints Industry Veteran Jon Kaplan to Board Mr. Kaplan brings a wealth of experience in business strategy specifically in healthcare and digital health New York, N.Y.
DarioHealth Corp. announced the appointment of Jon Kaplan to its board, effective immediately. Kaplan, a Managing Director at Boston Consulting Group, brings a wealth of experience in business strategy and digital health. His expertise is expected to bolster Dario's strategy at a pivotal time for the company, as it seeks to strengthen its market position and capitalize on the growing demand for scalable digital health solutions. The appointment reflects Dario's commitment to innovating healthcare management for individuals with chronic conditions.
Read more →DRIODario Partners to Integrate Dexcom CGM Data
DarioHealth Corp. announced a new agreement with Dexcom to integrate its continuous glucose monitoring (CGM) technology into Dario's multi-chronic condition digital platform. This integration will enhance the personalized support available to diabetes patients using CGMs, allowing for real-time glucose level monitoring within Dario's metabolic solutions. The collaboration builds on Dario's ongoing partnership with Sanofi US to provide innovative solutions in digital therapeutics for chronic health management. The integration aims to enrich Dario's data ecosystem and improve user experience across its platform.
Read more →DRIODarioHealth Announces Preliminary Fourth Quarter and Full Year 2022 Operating Results Preliminary Results demonstrate success in B2C to B2B transformation Total revenue for the year is expected to be $27.5 million compar
DarioHealth Corp. announced preliminary revenue results for 2022, highlighting a significant transformation from a Business-to-Consumer (B2C) model to a Business-to-Business (B2B) model. The company's revenue is expected to be around $27.5 million, reflecting a doubling from 2021's figure of $20.5 million, with B2B sales now constituting about 60% of total revenue. DarioHealth also reported a substantial reduction in operating loss, showcasing improved financial performance. This strategic shift is aimed at maximizing company value, with expectations for continued B2B growth in 2023.
Read more →DRIODario Adds New Senior Vice President of Growth to Expanding Sales Team
DarioHealth Corp. has appointed Matt Alberico as the new Senior Vice President of Growth to drive sales and capitalize on expanding opportunities. Alberico, who previously worked at Amazon Care, Cigna, and Aetna, is expected to leverage his experience to enhance Dario's market presence, especially following the signing of the 100th contract. He will oversee sales strategies and contribute to the development of Dario's digital health solutions aimed at chronic condition management. Additionally, he has been granted stock options as part of his employment package, aligning his incentives with the company's growth objectives.
Read more →DRIODario Publishes New Research in Peer Reviewed Journal Demonstrating Improved Outcomes by Race and Ethnicity
DarioHealth Corp. announced the publication of research in the journal Applied Sciences, highlighting improved diabetes outcomes for users across various racial and ethnic groups. The study analyzed data from 1,000 users with Type 2 diabetes over 12 months, revealing significant reductions in average blood glucose levels for all demographics. Dario's digital therapeutics platform effectively addresses health disparities, showcasing a commitment to enhancing health outcomes for a diverse population. The study underscores the importance of tailored digital health solutions in bridging healthcare divides.
Read more →DRIODario Achieves Goal of 100 Business-to-Business Contracts in 2022
DarioHealth Corp. achieved a significant milestone by signing 100 business-to-business contracts in 2022. A large Northeast U.S. supermarket chain will deploy Dario's cardiometabolic health solutions, which focus on diabetes, hypertension, and weight management. The success reflects a rising demand for integrated multi-condition management solutions in the employer market. Dario's innovative strategy emphasizes a holistic approach, combining technology with human support to enhance employee health and well-being.
Read more →DRIOLeading International Wellness Company Selects Dario as Partner for Musculoskeletal Health Improvement Program
Dario Move to be deployed in Greece and Cyprus to help improve the musculoskeletal health of the general populations New York, Dec. 22, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced toda
Read more →DRIONew Research Published in Peer Reviewed Journal Demonstrating Dario
NEW YORK, Dec. 19, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced the publication of a new study in the peer-reviewed journal Frontiers in Physiology today demonstrating the effectiveness
Read more →DRIOTwo New Employers Join Dario Through Benefits Brokerage Partner
The new accounts originated through an existing relationship with a benefits brokerage and provide further validation of Dario's partnership Strategy. NEW YORK, Dec. 1, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeu
Read more →DRIODario to Participate in Craig-Hallum and BTIG Digital Health
NEW YORK, Nov. 16, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today that management will participate at the following conferences: 13th Annual Craig-Hallum Alpha Select Conference Fo
Read more →DRIODarioHealth Reports Third Quarter 2022 Financial and Operating Results
Third quarter 2022 revenues of $6.6 million increased 17.3% from $5.6 million in the third quarter of 2021 driven by growth in Business-to-Business (B2B) revenues. Nine-month year to date revenue totaled $20.8 million, a 44% increase over the first nine months of 2021. B2B reven
Read more →DRIODarioHealth to Report Third Quarter 2022 Results on Monday, November 14th
Company to host conference call and webcast at 8:30 am ET the next day NEW YORK, Nov. 9, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the third quarter
Read more →DRIODario Announces Two Employer Contracts for Full Suite of Digital Health Solutions
New 'jumbo' employer account represents increasing penetration of the Dario platform NEW YORK, Oct. 20, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the company's full
Read more →DRIODario's Full Suite of Digital Solutions Selected by Midwestern City to Improve Employee Health DarioHealth Corp. ( Dario or the Company ) (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that a...
Dario to support City employees with integrated solutions addressing diabetes, hypertension, weight management, musculoskeletal and behavioral health in company's first government contract win NEW YORK, Oct. 13, 2022 /PRNewswire/ -- DarioHealth Corp. ("Dario" or the "Company") (
Read more →DRIODarioHealth Publishes New Clinical Research Linking the Use of its Biofeedback Device to Reduced Back Pain
New research sheds light on the importance of training to drive healthier posture NEW YORK, Sept. 22, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new research examining the link between the use
Read more →DRIODarioHealth Announces Two New Employer Contracts
New accounts demonstrate continued demand for integrated and holistic digital chronic condition management solutions NEW YORK, Sept. 20, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, an
Read more →DRIODarioHealth Reports Second Quarter 2022 Financial and Operating Results Q2 revenue of 6.2 million, a 17.5% increase from the $5.3 million of the second quarter of 2021. Six-month year-to-date revenue totaled $14.2 millio
DarioHealth Reports Second Quarter 2022 Financial and Operating Results Company to host conference call and webcast NEW YORK, August 15, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market,
Read more →DRIODarioHealth Presents New Research Demonstrating the Ability to Support People in Rural Areas and Deliver Lasting Health Improvements
The research examines Dario's ability to improve the health of members in rural areas compared to their urban counterparts and found the solution to be equally effective NEW YORK, Aug. 12, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital ther
Read more →DRIODarioHealth Selected by National Health Plan to Enhance Mental Health and Well-Being for Members
Dario's digital behavioral health solution will help to improve access and navigation across mental health resources NEW YORK, Aug. 11, 2022 /PRNewswire/ -- DarioHealth Corp. ("Dario", "DarioHealth" or the "Company") (Nasdaq: DRIO), a leader in the global digital therapeutics (D
Read more →DRIODarioHealth to Report Second Quarter 2022 Results on Monday, August 15
Company to host conference call and webcast at 8:30 am ET NEW YORK, Aug. 10, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the second quarter ended June
Read more →DRIODarioHealth Presents New Research Demonstrating the Impact of a Digital Solution on Depression and Anxiety at the American Psychological Association Annual Convention
The studies underscore the value of Dario's integrated behavioral health solution to help more people connect to effective care that is right for their needs NEW YORK, Aug. 4, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx
Read more →DRIODarioHealth Demonstrates Continued Growth in Multi-Chronic Contracts with Latest Addition of a National Employer for the Full Solution Suite
Demand for Dario's single approach to chronic condition management continues to show strong demand NEW YORK, July 21, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced a new contract to deliver its fu
Read more →DRIODarioHealth Announces New Contract with a National Employer
Dario continues to grow footprint in the employer market NEW YORK, June 21, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced a new contract to deliver its digital behavioral health solution for a lea
Read more →DRIODarioHealth Secures $50 Million Dollar Non-Dilutive Credit Facility with OrbiMed Investment from Elite Healthcare Fund Provides Validation, Access to Capital and Significant Runway to Execute on Strategic Operating Plan
DarioHealth Secures $50 Million Dollar Non-Dilutive Credit Facility Investment from Elite Healthcare Fund Provides Validation, Access to Capital and Significant Runway to Execute on Strategic Operating Plan NEW YORK, June 9, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO
Read more →DRIODarioHealth Presents Three New Studies Demonstrating Improved Health in Users with Multiple Conditions at the American Diabetes Association
The studies demonstrated significant improvement in glucose control and reductions in blood pressure for users managing diabetes and hypertension and improvement in clinical measures for users with diabetes, stress and depression. The third study demonstrates that the Dario solu
Read more →DRIODarioHealth Announces Additional Commercial Contracts for its Digital Therapeutic Solutions
Two new B2B contracts reinforce Dario's position as an emerging leader in multi-chronic digital health NEW YORK, May 19, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today two new contracts to provide
Read more →DRIODarioHealth Reports Record Quarterly Revenues in its 2022 First Quarter
Total Q1 revenue of $8.06 million increased 124% over the comparable prior year period and 34% sequentially over Q4 2021 Accelerated Business-to-Business (B2B) transformation with 14 new B2B accounts in Q1 2022, including two health plans Expanded GAAP gross margin to 49.4% and
Read more →DRIODarioHealth to Report First Quarter 2022 Results on Thursday, May 12
Company to host conference call and webcast at 8:30 am ET NEW YORK, May 4, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the first quarter ended March 31
Read more →DRIODarioHealth Presents New Clinical Research Demonstrating Improved Outcomes for Participants Using a Single Integrated Digital Solution to Manage Multiple Chronic Conditions
New research offers fresh evidence that a single digital therapeutics platform can improve outcomes for commonly co-occurring conditions NEW YORK, April 27, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced
Read more →DRIODarioHealth Announces Agreement with Health Plan Colorado Access
New health plan partnership improves access to digital health for historically underserved populations NEW YORK, April 14, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today a new agreement with Colora
Read more →DRIODarioHealth Announces Additional New Employer Contracts
NEW YORK, March 23, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today two new employer agreements: first, with a U.S. based social platform employer and second, with a global health care company. The c
Read more →DRIODarioHealth Reports Fourth Quarter and Full Year 2021 Results and Operational Highlights
NEW YORK, March 22, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today reported financial results for the fourth quarter and full year 2021 and provided a corporate and commercial update. "The last year complete
Read more →DRIODarioHealth to Report Fourth Quarter and Full Year 2021 Results on Monday, March 21
NEW YORK, March 14, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 21, 2022, afte
Read more →DRIODarioHealth Announces Two New Contracts within the Employer and Provider Market
NEW YORK, March 9, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new agreements with a regional employer and a regional provider. The contracts are expected to launch in the second quarter of 2022.
Read more →DRIODarioHealth to Participate in the Cowen 42nd Annual Healthcare Conference
NEW YORK, March 7, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced that management will participate in the Cowen 42nd Annual Healthcare Conference, which is being held virtually on March 7-9, 2022.
Read more →DRIODarioHealth Enters into Strategic Agreement with Sanofi U.S. Novel Strategic Agreement Focuses on Commercial Growth for Dario and the Development of Digital Health Solutions on Dario's Platform
DarioHealth Enters into Strategic Agreement Novel Strategic Agreement Focuses on Commercial Growth for Dario and the Development of Digital Health Solutions on Dario's Platform NEW YORK, March 1, 2022-- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeu
Read more →DRIODarioHealth Announced Pricing of its Registered Direct Offering for Aggregate Proceeds of $40 Million Priced At-The-Market Under Nasdaq Rules
NEW YORK, March 1, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that on February 28, 2022 it entered into definitive agreements with institutional investors, including insurance companies located
Read more →DRIODarioHealth Publishes Clinical Outcomes Demonstrating the Impact of Using a Single Digital Therapeutics Platform for Multiple Conditions
NEW YORK, Feb. 9, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced the publication of a retrospective, real-world study demonstrating the impact of managing blood pressure and diabetes together on the same
Read more →DRIODarioHealth Announces Four New Employer Contracts
NEW YORK, Feb. 8, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced several new contracts to deliver its digital therapeutics solutions for four new employers. The new accounts are expected to launch d
Read more →DRIODarioHealth Enters Agreement to Acquire Physimax, a Leading Provider of Validated Computer Vision for Musculoskeletal Health
NEW YORK, Jan. 20, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market (the Company), announced it has entered into an agreement to purchase all of the right, title and interest in certain assets of Physimax Technologies
Read more →DRIODarioHealth Enters into Agreement with Large Regional Health Plan
NEW YORK, Jan. 19, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ-CM: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it has contracted with a large regional health plan (the "Plan") to deliver its digital therapeutic solution for diabetes for eli
Read more →DRIODarioHealth to Host Investor Webinar on Navigating Emerging Digital Health Trends for Strategic Growth in 2022
NEW YORK, Jan. 18, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) a leader in the global digital therapeutics (DTx) market, today announced that it will host an investor webinar on navigating the emerging digital health trends in 2022 on Wednesday, January 19th at 8am ET.
Read more →DRIODarioHealth Announces Two New Contracts within the Employer Market
NEW YORK, Jan. 6, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced two new contracts today to provide its highly personalized digital therapeutics beginning in the first quarter of 2022. The new clients in
Read more →DRIODario Health - Investors Day Jan 19 th , 2022 This presentation and the statements of representatives and partners of DarioHealth Corp . (the "Company") related thereto contain or may contain forward - looking statements
1 Dario Health - Investors Day Jan 19 th , 2022 This presentation and the statements of representatives and partners of DarioHealth Corp . (the "Company") related thereto contain or may contain forward - looking statements within the meaning of the Private Securities Litigation
Read more →DRIODarioHealth Selected as Exclusive Digital Therapeutics Provider to a Leading Benefits Brokerage
NEW YORK, Dec. 21, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced a new strategic partnership with a leading employer benefits brokerage (the "Partner") to sell its digital therapeutic solutions for diabe
Read more →DRIODarioHealth Announces Two New Contracts within the Employer and Provider Markets
NEW YORK, Dec. 2, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced new contracts today to provide its highly personalized digital therapeutics beginning in the first quarter of 2022. The new clients include
Read more →DRIODarioHealth Reports Third Quarter 2021 Results and Operational Highlights
NEW YORK, Nov. 15, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the third quarter of 2021 and provided a corporate and commercial update. "The third quarter provided the strongest
Read more →DRIODarioHealth Appoints Seasoned Health Care Executive Jerrod Helms as Chief Commercial Officer
NEW YORK, Nov. 15, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the Company appointed Jerrod Helms to the newly created role of Chief Commercial Officer (CCO) to support the rapid expansion of bus
Read more →DRIODarioHealth Announces Three New Contracts as Growth Continues to Accelerate Across the Employer and Provider Markets
NEW YORK, Nov. 11, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has contracted with two new employers and a new provider partner channel to provide the Company's digital therapeutic soluti
Read more →DRIODarioHealth to Report Third Quarter 2021 Results on Monday, November 15
NEW YORK, Nov. 8, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the third quarter ended September 30, 2021 on Monday, November 15, 2021, after the close of tra
Read more →DRIODarioHealth to Participate in Upcoming Investor Conferences
NEW YORK, Nov. 5, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that management will participate at the following conferences: Credit Suisse 30th Annual Healthcare Conference Format: Investor one-on-o
Read more →DRIODarioHealth Partners with National Group Benefits Platform
NEW YORK, Nov. 3, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today a new strategic partnership with a leading national benefits administrative platform ("Benefits Platform"), to provide its full suite
Read more →DRIODarioHealth Gathers Momentum in the Provider Market with Two New Contracts for Remote Patient Monitoring Services
NEW YORK, Nov. 1, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into contracts with two prominent regional providers in Hawaii and Georgia for its Remote Patient Monitoring (RPM
Read more →DRIODarioHealth joins Virgin Pulse partner network
NEW YORK, Oct. 27, 2021 /PRNewswire/ -- DarioHealth today announced it has partnered with Virgin Pulse, the leading global provider of digital and live health and wellbeing solutions, making its next-gen digital therapeutic and health solutions available for contract through Virg
Read more →DRIODarioHealth Announces Contract with a U.S. National Employer to Provide Its Full Multi-Condition Suite Digital Therapeutic Solutions
NEW YORK, Oct. 25, 2021 /PRNewswire/ -- DarioHealth Corp. ("Dario," "DarioHealth" or the "Company") (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into a contract with a U.S. national employer (the "Employer") for the
Read more →DRIODarioHealth Unveils its Digital Musculoskeletal Solution Dario Move at HLTH 2021
BOSTON, Oct. 18, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today the launch of Dario Move, a new digital physical therapy solution to manage common musculoskeletal (MSK) conditions that drive signifi
Read more →DRIODarioHealth Announces Agreement with Leading National Health Plan
NEW YORK, Oct. 14, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it has entered into an agreement with one of the largest U.S. national health plans ("Plan") to offer its self-insured employer cust
Read more →DRIODarioHealth Announces Agreement with Global Employer for Metabolic and Musculoskeletal Health Solutions
NEW YORK, Oct. 7, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today an agreement with a global company based in the United States ("Company") to provide its integrated digital health management solutio
Read more →DRIODarioHealth to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference
NEW YORK, Sept. 24, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that management will participate in a fireside chat during the Cantor Fitzgerald Virtual Global Healthcare Conference, which is being he
Read more →DRIODarioHealth Chief Medical Officer Dr. Omar Manejwala to Speak at American Health Insurance Plans National Conference on Medicare, Medicaid and Dual Eligibles
NEW YORK, Sept. 17, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company's Chief Medical Officer, Dr. Omar Manejwala, will present at the annual American Health Insurance Plans National Confer
Read more →DRIODarioHealth Chosen by Northeast Regional Employer
Dario Continues to Expand its Employer Contracts Across Broad Range of Solutions NEW YORK, Sept. 9, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into an agreement to provide i
Read more →DRIODarioHealth Selected by Another Employer for Behavioral Health Services
NEW YORK, Sept. 8, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into an agreement to provide its digital behavioral health platform to a casino resort company ("Casino Resort C
Read more →DRIODarioHealth Chosen by Regional Primary Care Provider PeopleOne Health as its Digital Behavioral Health Partner
NEW YORK, Aug. 31, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has been selected by regional primary care provider PeopleOne Health to be the digital behavioral health solution of choice
Read more →DRIODarioHealth Reports Strong Second Quarter 2021 Results and Operational Highlights Total Q2 revenue of $5.3 million increased 46% sequentially and 194% year-over-year Validated B2B expansion by securing new clients in all
DarioHealth Reports Strong Second Quarter 2021 Results and Operational Highlights Total Q2 revenue of $5.3 million increased 46% sequentially and Validated B2B expansion by securing new clients in all B2B segments Expanded into the large and underserved digital behavioral hea
Read more →DRIODarioHealth Presents New Study Demonstrating Significant Clinical Impact of Personalized Digital Interventions Based on Real-Time Data
NEW YORK, Aug. 12, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced a new study at the American Association of Diabetes Care and Education Specialists (ADCES) annual conference demonstrating the impact of
Read more →DRIODarioHealth to Report Second Quarter 2021 Results on Monday, August 16
NEW YORK, Aug. 9, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the second quarter ended June 30, 2021 on Monday, August 16, 2021, and host a conference call a
Read more →DRIODarioHealth Behavioral Health Solution Selected by National Employer
NEW YORK, Aug. 4, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it has been selected as the digital behavioral health provider by a leading national professional services company. This new contract rep
Read more →DRIODarioHealth Launches Behavioral Health Solutions Globally in New Partnership with Workplace Options
NEW YORK, July 27, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced the launch of its digital behavioral health solution that now includes Workplace Options (WPO) services for its global users. WPO is the
Read more →DRIODarioHealth Chosen to Provide Remote Patient Monitoring for Alabama Regional Medical Services
NEW YORK, July 20, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it has been selected as a digital health provider by Alabama Regional Medical Services (ARMS), a Federally Qualified Health Center (FQHC)
Read more →DRIODarioHealth Chief Medical Officer Omar Manejwala, M.D., to Present on the Role of Digital Therapeutics in Post-Pandemic Healthcare at DTx Europe
NEW YORK, July 13, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced Chief Medical Officer Omar Manejwala, M.D. will present "Rebalancing: Digital Therapeutics in a Post-Pandemic Healthcare System" during th
Read more →DRIODarioHealth Expands Employer Footprint with Three New Contracts
NEW YORK, July 12, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced the launch of three new employer client contracts, including one global partnership, for the Company's new behavioral health solutio
Read more →DRIONew Research from DarioHealth Expands Evidence that Personalized Interventions Impact Health Behaviors and Improve User Engagement
NEW YORK, June 29, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, presented new clinical research today at the American Diabetes Association (ADA) 81st Scientific Sessions, the premier diabetes conference for cutti
Read more →DRIODarioHealth Remote Patient Monitoring Selected by Coastal Family Health Center to Improve Health of Patients with Hypertension
NEW YORK, June 24, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it has been selected as digital health provider by Coastal Family Health Center, a local, non-profit healthcare network providing compreh
Read more →DRIODarioHealth Expands Footprint in Musculoskeletal Sensor Technologies with the Upright GO S
NEW YORK, June 16, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today the launch of the Upright GO S, a new wearable sensor based on the company's pioneering biofeedback technologies to make better back
Read more →DRIODarioHealth to be Added to Russell 2000® and 3000® Indexes
NEW YORK, June 15, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell U.S. Indexe
Read more →DRIODarioHealth Announces Closing of wayForward Acquisition NEW YORK, June 8 2021 -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, today announced the consummation of the previo
DarioHealth Announces Closing of wayForward NEW YORK, June 8 2021 -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, today announced the consummation of the previously announced acquisition of PsyInnovations, Inc. (dba wayForward) t
Read more →DRIODarioHealth Releases Study Demonstrating the Impact of Personalized Digital Interventions to Improve Self-Management of Diabetes
Study results to be presented at the 14th International Conference on Advanced Technologies and Treatments for Diabetes NEW YORK, June 4, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it will be p
Read more →DRIODarioHealth to Participate in the Stifel 2021 Virtual Cross Sector Insight Conference
NEW YORK, June 3, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the company plans to participate in the upcoming Stifel 2021 Virtual Cross Sector Insight Conference. Erez Raphael, Chief Exec
Read more →DRIODarioHealth Publishes Research Confirming the Impact of a Digital Therapeutic Platform and Live Coaching on Diabetes Outcomes
NEW YORK,, May 27, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced the publication of a new study through a Letter to the Editor in the Journal of Diabetes Science and Technology. The study is titled "Dig
Read more →DRIODarioHealth to Participate in the Virtual 18th Annual Craig-Hallum Institutional Investor Conference
NEW YORK, May 26, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that management will participate in the 18th Annual Craig-Hallum Institutional Investor Conference, which is being held virtually on Wedne
Read more →DRIODarioHealth Acquires Digital Behavioral Health Platform wayForward
NEW YORK, May 18, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it has entered into an agreement to acquire PsyInnovations, Inc. (dba wayForward), a behavioral health digital platform that includes AI-e
Read more →DRIODarioHealth Reports First Quarter 2021 Results and Operational Highlights
NEW YORK, May 17, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the first quarter of 2021 and provided a corporate and commercial update. "During the first quarter, we delivered ex
Read more →DRIODarioHealth to Report First Quarter 2021 Results on Monday, May 17
NEW YORK, May 10, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the first quarter ended March 31, 2021 on Monday, May 17, 2021, after market close and host a c
Read more →DRIODarioHealth to Present at the Fifth International Vatican Conference
NEW YORK, May 6, 2021, /PRNewswire/ --DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that Rick Anderson, President and General Manager of North America, will participate in the Vatican's Pontifical Council for Culture
Read more →DRIODarioHealth Partners with MediOrbis on Virtual Care Offering for Diabetes
NEW YORK, April 20, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of a new virtual care initiative with MediOrbis, a telehealth provider specializing in chronic conditions. Eligible Medicare
Read more →DRIODarioHealth Reports Fourth Quarter and Full Year 2020 Results and Operational Highlights
NEW YORK, March 9, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the fourth quarter and full year 2020 and provided a corporate and commercial update. "The year 2020 was transforma
Read more →DRIODarioHealth Announces Participation in Stephens Virtual Best Ideas Conference
NEW YORK, March 5, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the company will participate in the upcoming Stephens 2021 Best Ideas Conference on March 11, 2021. Dario's CEO, Erez Raphael
Read more →DRIODarioHealth Study Examines Connection Between Personalization and Sustained Behavior Change in Digital Health
NEW YORK, March 2, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, today announced the results of a new clinical study that have been published in the Journal of Medical Internet Research (JMIR) Diabetes. The paper
Read more →DRIODarioHealth to Report Fourth Quarter and Full Year 2020 Results on Tuesday, March 9
NEW YORK, March 1, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the fourth quarter and full year ended December 31, 2020 on Tuesday, March 9, 2021, and host a
Read more →DRIODarioHealth Announces Participation in the Cowen 41st Annual Healthcare Conference
NEW YORK, Feb. 23, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference, a virtual event taking place March
Read more →DRIODarioHealth to Participate in 10th Annual SVB Leerink Global Healthcare Conference
NEW YORK, Feb. 19, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that Erez Raphael, Chief Executive Officer, and Rick Anderson, President and General Manager for North America are scheduled to par
Read more →DRIODarioHealth Corp. Nasdaq | DRIO AI - powered, digital solutions that drive durable behavior change in chronic disease 2 01 Forward Looking Statement This presentation of DarioHealth Corp. (the Company") and statements of
1 DarioHealth Corp. Nasdaq | DRIO AI - powered, digital solutions that drive durable behavior change in chronic disease 2 01 Forward Looking Statement This presentation of DarioHealth Corp. (the Company") and statements of our management or agents related thereto contain or m ay
Read more →DRIODarioHealth Announces Acquisition of Leading Digital Musculoskeletal Company Upright Technologies and $70 Million Financing Expands DarioHealth's multi-condition platform into the $213 billion musculoskeletal market and
Announces Acquisition of Leading Digital Musculoskeletal Company Upright Technologies and $70 Million Financing Expands DarioHealth's multi-condition platform into the $213 billion musculoskeletal market and creates one of the most comprehensive digital health platforms Financ
Read more →DRIODarioHealth Announces Hiring of Leading Digital Health Innovator as Senior Vice President of Employer Sales
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today the appointment of Chris Chan as Senior Vice President of Employer Sales. Mr. Chan will be responsible for leading growth initiativ
Read more →DRIODiabetes and Behavioral Health Global Experts Join DarioHealth Scientific Advisory Board Expanding Innovation Leadership in Digital Therapeutics for Chronic Care
NEW YORK, Jan. 13, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that Dr. Marilyn Ritholz and Dr. David Horwitz will join Chairman Eric Milledge on its Scientific Advisory Board (SAB), advancing D
Read more →DRIODarioHealth Appoints Claudia Rimerman Kraut as Vice President of Broker and Consultant Partnerships
NEW YORK, January 7, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the appointment of Claudia Rimerman Kraut as Vice President of Broker and Consultant Partnerships. In the newly created role, Ms. Kraut
Read more →DRIODarioHealth
NEW YORK, Jan. 5, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the Company has entered into an agreement to provide its digital therapeutics solution to eligible employees of a subsidiary of
Read more →DRIODarioHealth Announces Agreement with Presbyterian Medical Services for Remote Patient Monitoring
NEW YORK, Dec. 22, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the Company has entered into an agreement to provide its remote patient monitoring (RPM) solution to Presbyterian Medical Serv
Read more →DRIONew DarioHealth Study Shows Increased Digital Therapeutics Engagement Leads to Marked Reduction in Blood Glucose, Lower High Readings among Type 2 Diabetic Seniors
NEW YORK, Nov. 19, 2020 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, presented results from a new clinical study of 940 members at the 20th Annual Diabetes Technology Society Meeting (DTS), which showed a marked reduction
Read more →DRIODarioHealth Reports Third Quarter 2020 Results
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the third quarter 2020 and provided a corporate and commercial update. "During the third quarter we achieved 14.2%
Read more →DRIODarioHealth to Report Financial Results for the Third Quarter 2020 on November 12
NEW YORK, Nov. 4, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced it would release its second quarter ended September 30, 2020, financial results on Thursday, November 12, 2020,
Read more →DRIODarioHealth Announces Inclusion of its Digital Therapeutics Platform in Vitality Group
NEW YORK, Oct. 13, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced that Vitality Group has chosen the company's digital therapeutics solutions for inclusion in Vitality's new Gateway Flex offering. Gateway Fle
Read more →DRIODarioHealth and HMC HealthWorks Announce Partnership Agreement
NEW YORK and JUPITER, Fla., Sept. 21, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, and HMC HealthWorks, a 40-year veteran in healthcare management with clinically-integrated models of care that reduce healthcare costs
Read more →DRIODarioHealth Appoints Eric Milledge as Chairman of its Newly Established Scientific Advisory Board
NEW YORK, Sept. 16, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announces that Eric Milledge has joined DarioHealth as Chairman of the company's newly-established Scientific Advisory Board (SAB). Eric Milledge
Read more →DRIODarioHealth Announces Poster Presentation at the Virtual Association of Diabetes Care and Education Specialists 2020 Annual Conference
NEW YORK, Aug. 13, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that an emerging science industry poster has been accepted for presentation at the virtual Association of Diabetes Care and Education Spe
Read more →DRIODarioHealth Reports Second Quarter 2020 Results
NEW YORK, Aug. 12, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the second quarter 2020 and provided a corporate and commercial update. "The COVID-19 pandemic has accelerated our
Read more →DRIODarioHealth to Report Financial Results for the Second Quarter 2020 Results on August 12
NEW YORK, Aug. 7, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced it will release its second quarter ended June 30, 2020 financial results on Wednesday, August 12, 2020, and hos
Read more →DRIODarioHealth Announces $28.6 Million Private Placement
NEW YORK, July 31, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that it closed a private placement transaction with accredited investors, including healthcare funds and institutions from the U.S. and I
Read more →DRIODarioHealth Enters UK Remote Patient Monitoring (RPM) Market Through Agreement with Williams Medical
RHYMNEY, Wales and NEW YORK, July 20, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced that the company has entered into a new strategic partnership with Williams Medical to make the DarioHealth Remote Patient M
Read more →DRIODennis Matheis, President of Optima Health, a Multi-line Health Plan With More Than 850,000 Members and over 26,000 Providers, and Former President of Anthem Blue Cross and Blue Shield Central Region, Appointed to the Board of DarioHealth Corp
NEW YORK, July 6, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has appointed veteran health plan executive Dennis A. Matheis to its Board of Directors, effective July 2, 2020. Mr. Math
Read more →DRIODario Health to Host Key Opinion Leader Call on Digital Therapeutics for the Management of Diabetes and Other Chronic Conditions
NEW YORK, June 18, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that it will host a key opinion leader (KOL) call on digital therapeutics for the management of diabetes and other chronic conditions on
Read more →DRIODarioHealth Announces Participation in the Virtual Going Digital: Behavioral Health Tech Summit
NEW YORK, June 17, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that Omar Manejwala, M.D., Chief Medical Officer, will present at the virtual Going Digital: Behavioral Tech Summit. DarioHealth is also
Read more →DRIODarioHealth Presents New Studies Demonstrating Sustained Improvements in Blood Glucose and Blood Pressure Control in Users with Diabetes and Hypertension at the American Diabetes Association
NEW YORK, June 15, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leading global digital therapeutics (DTx) company, presented the results of two new studies at the American Diabetes Association's (ADA) 80th Scientific Sessions that showed sustained improvements in bloo
Read more →DRIODarioHealth Announces Two Remote Patient Monitoring (RPM) Agreements and Commences Enrollment
NEW YORK, June 11, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has signed its first two remote patient monitoring (RPM) agreements. Remote patient monitoring will allow treating physi
Read more →DRIODarioHealth Reports First Quarter 2020 Results
NEW YORK, May 12, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the first quarter 2020 and provided a corporate and commercial update. "In the first quarter of 2020, Dario executed
Read more →DRIODarioHealth Self-test Blood Glucose Meters Can Now Be Utilized Within Hospitals During the COVID-19 Pandemic Per Recently Issued Emergency FDA Guidelines
NEW YORK, May 6, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a global digital therapeutics (DTx) innovator, announced today that in an effort to reduce contact between healthcare providers and patients in hospital settings, limit COVID-19 exposure, and preserve persona
Read more →DRIODarioHealth to Report Financial Results for the First Quarter 2020 Results on May 12
NEW YORK, May 5, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced it will release its first quarter ended March 31, 2020 financial results on Tuesday, May 12, 2020, and host a co
Read more →DRIODarioHealth Expands Offering to Include Behavioral Health
NEW YORK, May 4, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leading global digital therapeutics (DTx) innovator, announced today that it has expanded its offering on its chronic care platform application to include behavioral health coaching for stress, anxiety and
Read more →DRIODarioHealth Expands Remote Care Offering With Integration of Full-Service Telemedicine
NEW YORK, April 29, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in global digital therapeutics (DTx), announced today a new partnership with value-based telemedicine provider MediOrbis to expand Dario's existing service offering with a full suite of telemedic
Read more →DRIODarioHealth® Announces Key New Hires Expanding Its Management Depth in the Employer and Managed Care Markets
NEW YORK, March 26, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced today the appointment of Omar Manejwala, M.D to the newly created position of Chief Medical Officer, and Barbara Stark as Senior Vice Presiden
Read more →DRIODario Diabetes Management Is Recognized as a Leading Application for Children/Young People Self-managing Healthcare During COVID-19 Pandemic
NEW YORK, March 25, 2020 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a global digital therapeutics (DTx) innovator, announced today an endorsement from the U.K. based ORCHA, highlighting the Company's Diabetes Management Application as being suitable and safe for children a
Read more →DRIODarioHealth Enters Into a Partnership With Vitality to Accelerate Penetration Into the Self-insured Employer Market
NEW YORK, March 24, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario") a pioneer in the global digital therapeutics market, announced today that it has entered into a partnership with Vitality Group, a global health and wellness company committed to making people hea
Read more →DRIODarioHealth Reports Fourth Quarter and Year End 2019 Results
NEW YORK, March 17, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a global digital therapeutics (DTx) innovator, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate and commercial update. Transformed the
Read more →DRIODarioHealth to Host Fourth Quarter 2019 Conference Call March 17, 2020
NEW YORK and CAESAREA, Israel, March 12, 2020 /PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) today announced it will release its fourth quarter and year end 2019 results on Tuesday, March 17, and host a conference call the same morn
Read more →DRIODarioHealth Appoints Two New Board Members
NEW YORK, March 5, 2020 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the company has appointed Yadin Shemmer and Adam K. Stern to serve as board members effective immediately until the 2020 Annual Meeting o
Read more →DRIODarioHealth Digital Diabetes Management System is Now Available at Albertsons
NEW YORK, Feb. 24, 2020 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of its digital therapeutics solution for managing chronic diseases such as diabetes and hypertension on Albertsons Marketplace
Read more →DRIODarioHealth® Presents New Clinical Study Outcomes Showing the Dario Digital Therapeutics Platform Helps Insulin Dependent Patients With Diabetes Better Manage Their Chronic Condition
NEW YORK, Feb. 19, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or "Dario"), a pioneer in the global digital therapeutics market, today presented a new clinical study at the Advanced Technologies & Treatments for Diabetes ("ATTD") conference in Madrid, Spa
Read more →DRIODarioHealth Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Jan. 31, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced today that on January 30, 2020, Richard Anderson was granted a non-qualified stock option award to purchase 90
Read more →DRIODarioHealth Strengthens Management Team With Appointment of Digital Health Veteran Rick Anderson as President and General Manager, North America
NEW YORK, Jan. 9, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced today the appointment of Richard Anderson as its President and General Manager of North America, effective Janu
Read more →DRIODarioHealth Announces Closing of $21.3 Million Private Placement
NEW YORK, Dec. 20, 2019 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced today that it has closed on a private placement of convertible preferred stock to institutional and private in
Read more →DRIOWalmart Starts Distributing the DarioHealth Digital Diabetes Management System
BENTONVILLE, Arkansas and NEW YORK, Dec. 3, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader, DarioHealth Corp. (NASDAQ: DRIO) announced today the launch of the Dario-powered digital diabetes program on Walmart.com. Walmart is the largest retailer in the world
Read more →DRIODarioHealth® Introduces "Membership-in-a-Box" to Brick and Mortar Retailers
NEW YORK, Nov. 25, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader, DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), announced today that its online membership offering will now be available for purchase in physical retail stores. The "Membership-in
Read more →DRIODarioHealth® Clinical Study Data Highlights the Material Benefit Digital Interventions Have on Glycemic Control in Users with Diabetes
NEW YORK and CAESAREA, Israel, Nov. 15, 2019 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or "Dario"), a leading global, digital therapeutics company, presented new clinical data yesterday at the 19th Annual Diabetes Technology Meeting ("DTM") conference in Bet
Read more →DRIODarioHealth Corp. CEO Erez Raphael Invited to Participate in BTIG Digital Health 2019
CAESAREA, Israel and NEW YORK, Nov. 14, 2019 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a leading, global digital therapeutics company, today announced that Dario's CEO, Erez Raphael, will be participating in a panel discussion at BTIG Digital He
Read more →DRIOAction Urgent Care Selects MyDario
SAN JOSE, California and NEW YORK, Nov. 12, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader, DarioHealth Corp. (NASDAQ: DRIO) announced today the launch of a Dario-powered digital diabetes program with Action Urgent Care. Action Urgent Care has experienced rap
Read more →DRIODarioHealth Reports Results for Third Quarter 2019
NEW YORK and CAESAREA, Israel, Oct. 28, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), today reported financial and operational results for the third quarter ended September 30, 2019. Q3 2019 Revenues of $1.87 million, a 13% sequenti
Read more →DRIODarioHealth Appoints Digital Therapeutics Pioneer Dr. Abigail Hirsch to Its Advisory Board to Support Commercial Strategy and Execution
CAESAREA, Israel and NEW YORK, Oct. 22, 2019 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a leading, global digital therapeutics company, has appointed Dr. Abigail Hirsch to its Advisory Board where she will help guide commercial and Business-to-Bu
Read more →DRIODarioHealth to Host Third Quarter 2019 Conference Call October 28, 2019
NEW YORK and CAESAREA, Israel, Oct. 17, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) today announced it will release its third quarter 2019 results on Monday, October 28, and host a conference call the same morning at 9:00 am
Read more →DRIODarioHealth CEO Erez Raphael Presents to Digital Therapeutics Leaders at DTx East 2019
NEW YORK and CAESAREA, Israel, Sept. 23, 2019 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a leading, global digital therapeutics company, today announced that Erez Raphael, DarioHealth's Chief Executive Officer, will be a speaker at the second ann
Read more →DRIODarioHealth Awarded U.S. Patent for Optical Transmission of Data Between a Sensor and Smart Device
NEW YORK and CAESAREA, Israel, Sept. 18, 2019 /PRNewswire/ -- DarioHealth Corp. ("DarioHealth" or "Dario") (Nasdaq: DRIO), a leading, global digital therapeutics company, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office titled "
Read more →DRIODarioHealth to Present at RHK Capital Disruptive Growth Conference on Thursday, September 5th
NEW YORK and CAESAREA, Israel, Aug. 28, 2019 /PRNewswire/ -- Leading global digital therapeutics company DarioHealth Corp. (Nasdaq: DRIO) today announced that DarioHealth's Chief Executive Officer, Erez Raphael, will present to and meet with investors and analysts attending the R
Read more →DRIODarioHealth Announces Alliance with DigitalHealth.London As Part of the UK Israel Dangoor Health Initiative
NEW YORK and CAESAREA, Israel, Aug. 15, 2019 /PRNewswire/ -- DarioHealth Corp. ("DarioHealth" or "Dario") (Nasdaq: DRIO), a leading, global digital therapeutics company, today announced an alliance with DigitalHealth.London ("DH.L") as part of its UK Israel Dangoor Health Initiat
Read more →DRIODarioHealth Reports Results For Second Quarter 2019
NEW YORK and CAESAREA, Israel, Aug. 13, 2019 /PRNewswire/ -- Q2 2019 Revenue of $1.65 million, a 20% decline from Q2 2018 Record 1H 2019 Revenue of $3.89 million, a 2% increase over 1H 2018 Expense shift from D2C to B2B, resulting in a short-term decline in Revenue and an expe
Read more →DRIODarioHealth® Clinical Study Data Shows the Dario Membership Program Assists Diabetes Patients in Achieving Pre-Diabetic Blood-Glucose Levels and Consistent In-Range Measurements
NEW YORK and CAESAREA, Israel, Aug. 12, 2019 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a leading global, digital therapeutics company, presented new clinical data yesterday at the American Association of Diabetes Educators ("AADE") conference in
Read more →DRIODarioHealth to Host Second Quarter 2019 Conference Call August 13, 2019
NEW YORK and CAESAREA, Israel, Aug. 7, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) today announced it will release its second quarter 2019 results on Tuesday, August 13, and host a conference call the same morning at 9:00 am
Read more →DRIODarioHealth to Present New Data at AADE Conference That Shows Improvement of Type 2 Diabetes Blood-glucose Levels Using MyDario™ App
NEW YORK and CAESAREA, Israel, Aug. 6, 2019 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or "Dario"), a leading global, digital therapeutics company and member of the Digital Therapeutics Alliance (DTx), today announced its plan to present the results of a new
Read more →DRIODarioHealth Launches New Blood Pressure Monitoring System
NEW YORK and CAESAREA, Israel, July 30, 2019 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), ("DarioHealth" or "Dario"), a leading global, digital therapeutics company, announced today the addition of a new digital monitoring solution on its Dario app platform that will allow p
Read more →DRIODarioHealth USB Type C Connector for the European Android Market Is CE Marked
NEW YORK and CAESAREA, Israel, July 25, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), today announced that its CE certificate covers a USB-C connector enabled version of the acclaimed Dario™ Blood Glucose Monitoring System. The USB-C
Read more →DRIODarioHealth Granted 180-day Extension by Nasdaq to Regain Compliance With bid Price Rule
NEW YORK and CAESAREA, Israel, July 8, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO) today announced that on July 5, 2019, it received notification from Nasdaq that the Company has been granted an additional 180-day compliance period,
Read more →DRIODarioHealth Reports Improvement in Glycemic Outcomes With Key Diabetes Findings at the American Diabetes Association
SAN FRANCISCO, June 11, 2019 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global Digital Therapeutics (DTx) company with connected devices, mobile software and large data solutions presented two studies reporting new real-world results at the American Diabetes Asso
Read more →DRIODarioHealth Signs New Functional Medicine Clinic to Its Digital Diabetes Platform
Functional Medicine Center of Fort Collins, in Fort Collins, CO will incorporate Dario's digital diabetes platform to its health and wellness improvement programs NEW YORK, CAESAREA, Israel and FORT COLLINS, Colorado, June 4, 2019 /PRNewswire/ -- Global #digitaltherapeutics inno
Read more →DRIODarioHealth to Present New Evidence of Digital Therapeutics Benefits at 2019 American Diabetes Association Conference
NEW YORK and CAESAREA, Israel, May 29, 2019 /PRNewswire/ -- Global digital therapeutics (DTx) innovator, DarioHealth Corp. (NASDAQ: DRIO), today announced its participation at the annual conference of the American Diabetes Association (ADA) in San Francisco on June 7th-10th. At
Read more →DRIODarioHealth Corp. Announces Pricing of $7.2 Million Public Offering of Common Stock
CAESAREA, Israel, May 22, 2019 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a global digital therapeutics innovator, today announced the pricing of an underwritten public offering of 4,855,341 shares of common stock at a price to the public o
Read more →DRIODarioHealth Corp. Live Therapeutics for Better Life Forward Looking Statements. This presentation of DarioHealth Corp. (the "Company") and statements of our managemen t contain or may contain forward - looking statements
1 DarioHealth Corp. Live Therapeutics for Better Life Forward Looking Statements. This presentation of DarioHealth Corp. (the "Company") and statements of our managemen t contain or may contain forward - looking statements within the meaning of the Private Securities Litigation
Read more →DRIODarioHealth Corp. Announces Commencement of Public Offering of Common Stock
CAESAREA, Israel, May 21, 2019 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a global digital therapeutics innovator, today announced that it intends to offer and sell shares of common stock (or pre-funded warrants in lieu thereof) in an under
Read more →DRIODarioHealth Reports Record Results For First Quarter 2019
CAESAREA, Israel, May 13, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), today reported record financial and operational results for the first quarter ended March 31, 2019. CEO, Erez Raphael, stated, "Our strong financial performance
Read more →DRIODarioHealth to Host First Quarter 2019 Conference Call May 13, 2019
NEW YORK and CAESAREA, Israel, May 7, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) today announced it will release its first quarter 2019 results on Monday, May 13, and host a conference call the same morning at 9:00 am EDT.
Read more →DRIODarioHealth Announces New Partnership With the American Diabetes Association
ARLINGTON, Virginia, NEW YORK and CAESAREA, Israel, May 3, 2019 /PRNewswire/ -- Global digital therapeutics innovator, DarioHealth Corp. (NASDAQ: DRIO), today announced that it is partnering with the American Diabetes Association as a Living Red Sponsor of NYC - Step Out®: Walk t
Read more →DRIODarioⓇ Becomes a Member of the Digital Therapeutics Alliance
WASHINGTON and CAESAREA, Israel, April 30, 2019 /PRNewswire/ -- Global digital therapeutics innovator, DarioHealth Corp. (NASDAQ: DRIO), today announced that it is now a member of the Digital Therapeutics Alliance (DTA) (www.DTxAlliance.org). Dario's acceptance to the DTA as a n
Read more →DRIODario® Elevates Digital Therapeutics Capabilities by Further Enhancing Patient Experience
CAESAREA, Israel, April 10, 2019 /PRNewswire/ -- Global digital therapeutics innovator, DarioHealth Corp. (NASDAQ: DRIO), today announced the launch of a new version of its acclaimed Dario® system and DarioEngage™ platform. The enhancements in the updated platform target three k
Read more →DRIODarioHealth Signs Leading Functional Medicine Clinic to DarioEngage™ Remote Digital Diabetes Platform
NEW YORK and CAESAREA, Israel, April 1, 2019 /PRNewswire/ -- Global #digitaltherapeutics innovator DarioHealth Corp. (Nasdaq: DRIO) today announced an agreement with Cupertino-based Auer Integrative Health's Functional Medicine and Chiropractic, a Silicon Valley medical clinic.
Read more →DRIODarioHealth Partners With Glytec on Outpatient Diabetes Management
CAESAREA, Israel and WALTHAM, Massachusetts, March 27, 2019 /PRNewswire/ -- Global digital therapeutics innovator, DarioHealth Corp. (NASDAQ: DRIO), today announced a joint marketing agreement with Glytec, the market leader and pioneer of insulin titration solutions for use acros
Read more →DRIODarioHealth Reports Fourth Quarter and Year End 2018 Record Results
CAESAREA, Israel, March 25, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), today reported record financial and operational results for the full-year ended on December 31, 2018. Financial Highlights Record annual revenues of $7.4 mil
Read more →DRIODarioHealth Granted License by Health Canada to Sell Dario Smart Glucose Meters for Lightning® Connector Enabled iPhones
NEW YORK and CAESAREA, Israel, March 20, 2019 /PRNewswire/ -- Global digital therapeutics innovator, DarioHealth Corp. (NASDAQ: DRIO), announced today the receipt of a license from Health Canada to sell its Dario™ Blood Glucose Monitoring System for Lightning power connector-enab
Read more →DRIODarioHealth to Host Fourth Quarter and Year End 2018 Conference Call March 25, 2019
NEW YORK and CAESAREA, Israel, March 18, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) today announced it will release its fourth quarter and year-end 2018 results on Monday, March 25, and host a conference call the same morni
Read more →DRIODarioHealth Signs National Distribution Deal in the U.S. With Better Living Now for Its Digital Health Products
NEW YORK and CAESAREA, Israel, Jan. 2, 2019 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today it has signed an agreement with Better Living Now (BLN), a leading national healthcare
Read more →DRIODarioHealth to Offer Diabetes Content and Coaching to Patients in Canada in Collaboration With LMC Healthcare, Canada
CAESAREA, Israel, Dec. 12, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that Toronto-based LMC Healthcare, Canada's largest specialist care provider in diabetes and endocr
Read more →DRIODarioHealth Reports Third Quarter 2018 Results
NEW YORK and CAESAREA, Israel, Nov. 13, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today reported financial and operational results for the third quarter ended September 30, 2018. "We
Read more →DRIODarioHealth to Host Third Quarter 2018 Conference Call on November 13, 2018
NEW YORK and CAESAREA, Israel, Nov. 6, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will release its third quarter 2018 results on Tuesday, November 13, and host a
Read more →DRIODarioHealth Launches Integrated Diabetes Digital Health Solution Including Version 4.1 of Its Award-winning Dario App and DarioEngage Patient Coaching Platform
CAESAREA , Israel, Oct. 25, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today the launch of version 4.1 of its award-winning Dario® App for the Dario Blood Glucose Monitoring S
Read more →DRIODarioHealth Appoints Glen D. Moller, Healthcare Executive, Investor and Former CEO of ArroHealth, to Its Board of Directors
CAESAREA, Israel, Oct. 18, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that Glen Moller has joined the Company's Board of Directors. Mr. Moller is a highly regarded healt
Read more →DRIODarioHealth to Host Investor Conference Call on October 4, 2018
CAESAREA, Israel, Sept. 20, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will host a conference call to provide a business update for investors at 9:00am EDT on Th
Read more →DRIODarioHealth Closes on $10,345,000 Through Private Placement Offering
CAESAREA, Israel, Sept. 14, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that it has closed on a private placement offering with institutional and private investors for th
Read more →DRIODarioHealth Appoints Olivier Jarry, Former Head of Diabetes Care at Bayer and Executive at Novartis and Bristol-Myers-Squibb, as President and Chief Commercial Officer
CAESAREA, Israel, Sept. 5, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that Olivier Jarry, a prominent global life sciences and consumer health executive, has joined the
Read more →DRIODarioHealth Chosen by Attain Health for Pilot Study to Improve Cystic Fibrosis Related Diabetes Management
CAESAREA, Israel, Aug. 22, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today it has entered into an agreement with Attain Health, a provider of integrative health coaching for
Read more →DRIODarioHealth to Exhibit at American Association of Diabetes Educators Conference on August 17-20 in Baltimore
CAESAREA, Israel, Aug. 15, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today it will exhibit the DarioEngage platform and its other digital health products at the American Asso
Read more →DRIODarioHealth Reports Second Quarter 2018 Results
NEW YORK and CAESAREA, Israel, Aug. 9, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today reported financial and operational results for the second quarter ended June 30, 2018. Second Qu
Read more →DRIODarioHealth to Host Second Quarter 2018 Conference Call on August 9, 2018
NEW YORK and CAESAREA, Israel, Aug. 1, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will release its second quarter 2018 results on Thursday, August 9th and host a
Read more →DRIODarioHealth Launches New Annual Membership & Product Enhancements to Promote Long-Term Use, Higher Levels of User Engagement, and Associated Sustainable Behavioral Changes
CAESAREA, Israel, July 25, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that following new data presented at the American Diabetes Association (ADA) on June 25, 2018 showi
Read more →DRIODarioHealth CEO Erez Raphael
CAESAREA, Israel, July 12, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that Research2Guidance, an analyst and strategic consulting company for the digital health industry
Read more →DRIODarioHealth Appoints Healthcare Technology Entrepreneur and Venture Capital Partner Yoav Shaked as Chairman of the Board
CAESAREA, Israel, July 9, 2018 /PRNewswire/ --– DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today Yoav Shaked has joined the Company as Chairman of the Board. The Company's Chief Executive Officer,
Read more →DRIODarioHealth Presents New Data at American Diabetes Association
CAESAREA, Israel, June 25, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today reported new data at the American Diabetes Association's (ADA) 78th Scientific Sessions which takes place in
Read more →DRIODarioHealth to Deliver Three Poster Presentations With New Data at American Diabetes Association on June 25, 2018
NEW YORK and CAESAREA, Israel, June 21, 2018 DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced JC Muyl, the Company's Head of Commercialization for North America, will deliver three poster presenta
Read more →DRIODarioHealth Set to Join Russell Microcap® Index Effective June 25, 2018
NEW YORK and CAESAREA, Israel, June 19, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that its stock will be added to the Russell Microcap® Index, effective at market open
Read more →DRIODarioHealth Provides Update on Recently Launched iPhone 7, 8 and X Smart Glucose Meter in the U.S. Following FDA Clearance
NEW YORK and CAESAREA, Israel, June 7, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today it has experienced a successful launch of its iPhone® 7, 8 and X compatible Blood Gluco
Read more →DRIODarioHealth to Present at Chardan
SAN FRANCISCO, May 21, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that Erez Raphael, Chairman and CEO of DarioHealth, will be delivering a presentation at Chardan's Digi
Read more →DRIODarioHealth Reports First Quarter 2018 Results
NEW YORK and CAESAREA, Israel, May 15, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today reported financial and operational results for the first quarter ended on March 31, 2018. First
Read more →DRIODarioHealth Releases Next Generation Version 4.0 of its Award-Winning App
NEW YORK and CAESAREA, Israel, May 8, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced the availability of its award-winning next-generation app, version 4.0. The upgraded us
Read more →DRIODarioHealth to Host First Quarter 2018 Conference Call on May 15, 2018
NEW YORK and CAESAREA, Israel, May 2, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will release its first quarter 2018 results on Tuesday, May 15th and host a conf
Read more →DRIODarioHealth Ramps up Commercialization Capabilities
NEW YORK and CAESAREA, Israel, April 30, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today it has hired U.S.-based digital health executive JC Muyl as Head of Commercialization
Read more →DRIODarioHealth Launches Customer Hotline to Pre-Order Its Apple iPhone Lightning-Compatible Glucose Monitor in the U.S.
NEW YORK and CAESAREA, Israel, March 29, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced it will offer its past and current subscription holders the option to pre-order its f
Read more →DRIODarioHealth Receives U.S. FDA Clearance for iPhone 7, 8 and iPhone X Smart Glucose Meter
NEW YORK and CAESAREA, Israel, March 26, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that the United States Food and Drug Administration (FDA) has granted Pre-market Noti
Read more →DRIODarioHealth Reports Fourth Quarter and Year End 2017 Results
CAESAREA, Israel, March 19, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today reported financial and operational results for the fourth quarter and full-year periods ended on December 31
Read more →DRIODarioHealth Announces Revised Date for Fourth Quarter and Year End 2017 Conference Call
NEW YORK and CAESAREA, Israel, March 14, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that the previously announced earnings release and conference call to report its four
Read more →DRIODarioHealth to Host Fourth Quarter and Year End 2017 Conference Call on March 20, 2018
NEW YORK and CAESAREA, Israel, March 8, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will release its fourth quarter and year end 2017 results on Tuesday, March 20
Read more →DRIODarioHealth Presents Dario Engage Vision at the HIMSS Annual Conference & Exhibition
LAS VEGAS, Mar 5, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced it is sharing its Dario Engage vision of moving diabetes management to focus on personalization this week at
Read more →DRIODarioHealth Launches Sales of Dario™ Blood Glucose Monitoring System on Amazon Prime
NEW YORK and CAESAREA, Israel, Feb. 20, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today the launch and first sales of its Dario™ Blood Glucose Monitoring System on Amazon. D
Read more →DRIODarioHealth Partners With a Leading Diabetes Clinic
NEW YORK and CAESAREA, Israel, Feb. 12, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced it has partnered with the Diabetes and Endocrinology Consultants of Pennsylvania, LLC,
Read more →DRIODarioHealth Wins Key Contract Ensuring Its Platform to be Utilized in Clinical Study
NEW YORK and CAESAREA, Israel, Feb. 8, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced it has entered into an agreement with a pharmaceutical company conducting a clinical st
Read more →DRIODarioHealth Introduces iPhone 7, iPhone 8, and iPhone X Compatible Smart Glucose Meter to the Australian Market
CAESAREA, Israel, Jan. 17, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced it has launched the Lightning®-enabled version of the acclaimed Dario™ Blood Glucose Monitoring Sys
Read more →DRIODarioHealth Begins Selling iPhone 7, iPhone 8, and iPhone X Smart Glucose Meter in the U.K.
CAESAREA, Israel, Jan. 8, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced it has successfully sold the first Lightning®-enabled version of the acclaimed Dario™ Blood Glucose
Read more →DRIODarioHealth Granted Another U.S. Patent Strengthening its Core Technology
CAESAREA, Israel, Dec. 27, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced the U.S. Patent and Trademark Office has issued the Company patent #9832301 titled "Systems and Met
Read more →DRIODarioHealth Gains Regulatory Approval in Australia for iPhone 7, iPhone 8, and iPhone X Smart Glucose Meter
CAESAREA, Israel, Dec. 18, 2017 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that it received the Therapeutic Goods Administration (TGA) Mark for its Lightning®-enabled version
Read more →DRIODarioHealth Launches Version 3.5 of its MyDario App to Support iPhone 7 and iPhone 8
CAESAREA, Israel, Nov. 20, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced the availability of update version 3.5 of its MyDario app. The app update includes support for Dari
Read more →DRIODarioHealth Reports Third Quarter 2017 Results
CAESAREA, Israel, Nov. 14, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today reported financial and operational results for the three-month period ended September 30, 2017. Third Quarte
Read more →DRIODarioHealth to Host Third Quarter Conference Call on November 14, 2017
CAESAREA, Israel, Nov 6, 2017, /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will release its third quarter 2017 results on Tuesday, November 14 and host a conference ca
Read more →DRIODarioHealth Expanding its Mobile Health and Data Offerings to Include a Business-to-Business Solution
CAESAREA, Israel, Oct. 30, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that it is increasing its B2B2C offering by facilitating organizations to digitize targeted health
Read more →DRIODarioHealth Gains CE Mark for iPhone 7 and iPhone 8 Smart Glucose Meter
CAESAREA, Israel, Oct. 18, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that it received the CE Mark for its Lightning®-enabled version of the acclaimed Dario™ Blood Gluco
Read more →DRIODarioHealth Launches into the German Diabetes Market
CAESAREA, Israel, Oct. 3, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced it expands its global reach with a successful launch into the German market, making its smart diabet
Read more →DRIODarioHealth Launches Its Dario App in the Google Play Store Expanding Its U.S. Market Reach
CAESAREA, Israel, Sept. 7, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced the launch of its Dario app for certain leading Android smart mobile devices (SMD) in the U.S. The
Read more →DRIODarioHealth Closes on $5 Million Through Private Placement Offerings
CAESAREA, Israel, Aug. 23, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health Company with mobile health and big data solutions, announced today that it has closed on concurrent private placement offerings with domestic and non-U.S. investors f
Read more →DRIODarioHealth Reports Second Quarter 2017 Results
CAESAREA, Israel, August 14, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today reported financial and operational results for the three-month period ended June 30, 2017. Second Quarter
Read more →DRIODarioHealth to Host Second Quarter Conference Call on August 14, 2017
CAESAREA, Israel, Aug. 11, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will release its second quarter 2017 results on Monday, August 14 and host a conference cal
Read more →DRIODarioHealth Partners with Byram Healthcare to Further Expand Insurance Health Coverage for U.S. Consumers
CAESAREA, Israel and NEW YORK, July 25, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it is expanding its insurance coverage provider network by entering into a strate
Read more →DRIODarioHealth Announces Strategic Partnership with CCS Medical
DarioHealth Corp. has announced a strategic partnership with CCS Medical to enhance diabetes management through the LivingConnected clinical program. This collaboration will provide live data access for patients using DarioHealth's app, improving real-time monitoring and support. The partnership aims to strengthen DarioHealth's position in the U.S. market and expand its insurance reimbursement options.
Read more →DRIODarioHealth Receives U.S. FDA Clearance for Certain Leading Android Devices in the U.S.
DarioHealth Corp. has received FDA clearance for its Dario app on select Android devices, including Samsung and LG models. This approval allows the company to expand its market presence in the U.S. and launch its flagship app on the Google Play Store. The CEO expressed excitement over this milestone and its potential for growth.
Read more →DRIODarioHealth Receives "First Choice" Recognition in the UK
DarioHealth Corp. has been recognized as the 'First Choice' for type 1 diabetes management by Clinical Commissioning Groups in three UK regions. This designation is expected to enhance the company's market presence as healthcare professionals increasingly adopt Dario's innovative diabetes management solutions. The compact design and functionality of the Dario system have received positive feedback from both users and healthcare providers.
Read more →DRIODarioHealth Looks to Accelerate Market Penetration with Expanded Health Insurance Coverage to Target up to 10 Million Consumers
CAESAREA, Israel, June 21, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it is expanding its insurance coverage provider network across the U.S. with additional servic
Read more →DRIODarioHealth Launching New Social Initiative at ADA
CAESAREA, Israel, June 5, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it is launching a new social initiative called DarioCares™ at the American Diabetes Association
Read more →DRIODarioHealth to Present at the 7th Annual LD Micro Invitational
CAESAREA, Israel, May 30, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will be presenting at the 7th annual LD Micro Invitational on Tuesday, June 6, 2017, at 8:00
Read more →DRIOLazier Racing Partners Teams Up with DarioHealth for the Indy 500
CAESAREA, Israel and INDIANAPOLIS, May 24, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it is partnering with Lazier Racing Partners and driver Buddy Lazier to raise
Read more →DRIODarioHealth Adds Former Bayer Diabetes Executive and Visionary to its Advisory Board
CAESAREA, Israel, May 17, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it signed global life sciences and consumer health executive, Olivier Jarry, to a Strategic Adv
Read more →DRIODarioHealth Reports First Quarter 2017 Results
CAESAREA, Israel, May 15, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today reported financial and operational results for the three month period ended March 31, 2017. First Quarter Hig
Read more →DRIODarioHealth to Host First Quarter Conference Call on May 15, 2017
CAESAREA, Israel, May 9, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will release its first quarter 2017 results on Monday, May 15 and host a conference call at 9
Read more →DRIODarioHealth Lowers Diabetes Healthcare Costs in Canada
CAESAREA, Israel, May 4, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it is teaming up with Auto Control Medical, an A&D Company, and STI Technologies Limited to lowe
Read more →DRIODarioHealth Expands Global Presence With Direct-to-Consumer Launch in the U.K.
CAESAREA, Israel, April 26, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced the launch of a direct-to-consumer channel in the United Kingdom. Following the success of the dir
Read more →DRIODarioHealth Signs NBA Legend Dominique Wilkins as Brand Ambassador
CAESAREA, Israel and ATLANTA, April 19, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced a brand ambassador partnership with NBA great and Naismith Memorial Basketball Hall of
Read more →DRIODARIOHEALTH CORP. PRICES OFFERING OF 1,450,000
CORP. PRICES OFFERING OF 1,450,000 SHARES OF COMMON STOCK ISRAEL, March 31, 2017 - DARIOHEALTH CORP. ("DARIO") (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced the pricing of an underwritten public offering of 1,450,0
Read more →DRIODarioHealth Corp. Prices Offering of 1,450,000 Shares of Common Stock
CAESAREA, Israel, March 31, 2017 /PRNewswire/ --DarioHealth Corp. ("DARIO") (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced the pricing of an underwritten public offering of 1,450,000 shares of its common stock at a pub
Read more →DRIODarioHealth Corp. Announces Proposed Public Offering of Common Stock
CAESAREA, Israel, March 30, 2017 /PRNewswire/ -- DARIOHEALTH CORP. ("DARIO") (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced that it intends to offer for sale shares of its common stock in an underwritten public offeri
Read more →DRIODarioHealth Launches Insurance Coverage Option for U.S. Consumers
CAESAREA, Israel, March 27, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it is now offering a 3rd party insurance coverage option for U.S. consumers who want to have
Read more →DRIODarioHealth Reports Fourth Quarter and Year End 2016 Results
CAESAREA, Israel, March 22, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today reported financial and operational results for the three and twelve month period ended December 31, 2016. R
Read more →DRIODarioHealth to Host Fourth Quarter and Year End 2016 Conference Call on March 23, 2017
CAESAREA, Israel, March 20, 2017 /PRNewswire/ -- Earnings and Business Update Conference Call Scheduled for 9:00am ET DarioHealth Corp. (NASDAQ: DRIO), a leader in digital health and mobile health solutions and the developer of the Dario™ Blood Glucose Monitoring System, announ
Read more →DRIODarioHealth Corp. Strengthens Board of Directors with Two Additional Appointments
CAESAREA, Israel, March 2, 2017 /PRNewswire/ -- Two new board members are Managing Partners at OurCrowd Qure New board members Dr. Yossi Bahagon and Allen Kamer bring unique vision and years of successful digital health executive and entrepreneurship experience DarioHealth Cor
Read more →DRIODarioHealth to Present at the OurCrowd Global Investor Summit
BOSTON, Feb. 8, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in digital health and mobile health solutions and the developer of the Dario™ Blood Glucose Monitoring System, an all-in-one diabetes meter, today announced that its Chairman and Chief Executive Offic
Read more →DRIODarioHealth Corp. Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation BOSTON and JERUSALEM, Feb. 6, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), based in Boston and Jerusalem, focused on digital heal
Read more →DRIODarioHealth Corp. to Webcast, Live, at VirtualInvestorConferences.com February 2
BOSTON and JERUSALEM, Jan. 30, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), based in Boston and Jerusalem, focused on digital health and mobile health solutions, today announced that Erez Raphael, Chairman & CEO, will present live at VirtualInvestorConferences.com on Fe
Read more →DRIODarioHealth Accelerates U.S. Device Sales and Consumable Strips Growth in Fourth Quarter
BOSTON, Jan. 23, 2017 /PRNewswire/ -- Direct-to-consumer digital marketing strategy drives 85% sequential increase in U.S. devices sold and 65% increase in consumable sales, quarter-over-quarter DarioHealth Corp. (NASDAQ: DRIO), a leader in digital health and mobile health solu
Read more →DRIODarioHealth Corp. Announces $5.1 Million Private Placement Led by OurCrowd Qure - Israeli Digital Health Specialized Fund
BOSTON and JERUSALEM, Jan. 12, 2017 /PRNewswire/ -- Deal led by OurCrowd Qure, a dedicated digital health fund that invested $2.5 million of the $5.1 million. Current investors of DarioHealth also participated in the current round indicating the strong support and belief in the
Read more →DRIODarioHealth Reports Third Quarter 2016 Results
BOSTON, Nov. 10, 2016 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), developer of the Dario™ Blood Glucose Monitoring System, today reported financial and operational results for the three and nine month periods ended September 30, 2016. Third Quarter 2016 Highlights Record
Read more →DRIODarioHealth to Host Third Quarter 2016 Conference Call on November 11, 2016
BOSTON, Nov. 7, 2016 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in digital health and mobile health solutions and the developer of the Dario™ Blood Glucose Monitoring System, an all-in-one diabetes meter, announced today that it will release its third quarter 2016
Read more →DRIODarioHealth Reports Successful Traction for Dario
BOSTON, Oct. 25, 2016 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO), a leader in digital health and mobile health solutions and the developer of the Dario™ Blood Glucose Monitoring System, an all-in-one diabetes meter, today announced continued adoption for its revolutionary mo
Read more →DRIODarioHealth Launches New Digital Platform and Online Store in Canada
BOSTON, Sept. 27, 2016 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO), a leader in digital health and mobile health solutions and the developer of the Dario™ Smart Diabetes Management Solution, today announced the launch of an online store in Canada. This is in collaboration wit
Read more →DRIODarioHealth Preps for New iPhone
BOSTON, Sept. 8, 2016 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), developer of the Dario™ Blood Glucose Monitoring System, today announced that it is adapting its flagship product to also incorporate use with the new Apple® iPhone® 7. After receiving regulatory clearance fo
Read more →DRIODarioHealth Reports Second Quarter 2016 Results
BOSTON, Aug. 11, 2016 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), developer of the Dario™ Blood Glucose Monitoring System, today reported financial and operational results for the three and six month period ended June 30, 2016. Second Quarter 2016 Highlights Record high r
Read more →DRIODarioHealth is Now Direct-to-Consumer in Australia
BOSTON, July 28, 2016 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO), a leader in digital health and mobile health solutions and the developer of the Dario(TM) Smart Diabetes Management Solution, today announced that it has begun offering the Dario Smart Diabetes Management Sol
Read more →DRIODigital Health Innovators Company Overview - July 2016
Digital Health Innovators Company Overview - July 2016 Digital Health Innovators This presentation of DarioHealth (the "Company") and statements of our management or agents related thereto contain or may contain forward - looking statements within the meaning of the Private Secu
Read more →DRIOLabStyle Innovations Corp.
LabStyle Innovations Corp. 9 Halamish Street, P.O.B. 3052 Caesarea Industrial Park To the Stockholders of LabStyle Innovations LabStyle Innovations Corp. (the "Company") is pleased to send you the enclosed notice of the 2015 Annual Meeting of Stockholders of the Company (the
Read more →DRIOLabStyle Innovations Raises $1.6 Million in a Non-Brokered Private Placement Financing Proceeds to fund manufacturing, sales and marketing programs for LabStyle's Dario TM as well as ongoing FDA efforts
LabStyle Innovations Raises $1.6 Million Private Placement Financing Proceeds to fund manufacturing, sales and marketing programs for LabStyle's DarioTM as well as ongoing FDA efforts CAESAREA, Israel - February 25, 2015 /PRNewswire/ - LabStyle Innovations Corp. (OTCQB:DRIO)
Read more →DRIOLabStyle Innovations Appoints Zvi Ben-David as New Chief Financial Officer Brings 25 years of medical device finance and accounting expertise to LabStyle Current CFO Gadi Levin to remain in transition as advisor and busi
LabStyle Innovations Appoints Zvi Ben-David as New Chief Financial Officer Brings 25 years of medical device finance and accounting expertise to LabStyle Current CFO Gadi Levin to remain in transition as advisor and business development consultant Jan. 8, 2015 /PRNewswire/
Read more →DRIOLabStyle Innovations Closes $4.2 Million
Contacts: Press Investor Relations Brenda Zeitlin LabStyle Innovations Booke and Company Inc. 1 212 490 9095 1 800 896 9062 admin@bookeandco.com Brenda@mydario.com LabStyle Innovations Closes $4.2 Million Private Placement Financing Proceeds to drive manufacturing, sales an
Read more →DRIOLabStyle Innovations Corp. 9 Halamish Street Caesarea Industrial Park 38900, Israel SUPPLEMENT TO PROXY STATEMENT FOR 2014 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON TUESDAY, JUNE 10, 2014 NOTICE OF CHANGE OF DIRECTOR
LabStyle Innovations Corp. Caesarea Industrial Park SUPPLEMENT TO PROXY STATEMENT FOR 2014 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON TUESDAY, JUNE 10, 2014 NOTICE OF CHANGE OF DIRECTOR ELECTION CHANGE OF MEETING DATE REVISED MEETING DATE: TUESDAY, JUNE 17, To Our Stock
Read more →DRIOLabStyle Innovations Corp. 9 Halamish Street Caesarea Industrial Park 38900, Israel
LabStyle Innovations Corp. Caesarea Industrial Park To the Stockholders of LabStyle Innovations LabStyle Innovations Corp. (the "Company") is pleased to send you the enclosed notice of the 2014 Annual Meeting of Stockholders of the Company (the "Meeting") to be held at 11:00
Read more →DRIOLabStyle Innovations Announces Pricing of $4.19 Million Private Placement Financing Caesarea, Israel
LabStyle Innovations Announces Pricing Private Placement Financing Caesarea, Israel, February 13, 2014 --- LabStyle Innovations Corp. (OTCQB:DRIO), developer of the Dario Diabetes Management Platform today announced that it has entered into a definitive securities purchase ag
Read more →DRIOLabStyle Innovations Appoints Mr. Gadi Levin as Chief Financial Officer Experienced public company CFO augments LabStyle's senior management capabilities as the company moves towards commercial launch of Dario TM Separat
LabStyle Innovations Appoints Mr. Gadi Levin as Chief Financial Officer Experienced public company CFO augments LabStyle's senior management capabilities as the company moves towards commercial launch of DarioTM Separately, Professor Itamar Raz steps down from LabStyle's Boa
Read more →DRIOMarjie Hadad Press Investor Relations LabStyle Innovations Booke and Company, Inc. +972-54-536-5220 +1-212-490-9095 marjie@netvision.net.il admin@bookeandco.com LabStyle Innovations Welcomes Dennis M. McGrath t
Contacts: Marjie Hadad Press Investor Relations LabStyle Innovations Booke and Company, Inc. +972-54-536-5220 +1-212-490-9095 marjie@netvision.net.il admin@bookeandco.com LabStyle Innovations Welcomes Dennis M. McGrath to its Board of Directors Senior medical device industry
Read more →DRIOLABSTYLE INNOVATIONS ANNOUNCES INTERNAL MANAGEMENT CHANGES IN ANTICIPATION OF COMMERCIAL LAUNCH OF DARIO Moves underscore evolution from R&D to commercial-stage enterprise European approval of Dario blood glucose monitor
LABSTYLE INNOVATIONS ANNOUNCES INTERNAL IN ANTICIPATION OF COMMERCIAL LAUNCH Moves underscore evolution from R&D to commercial-stage enterprise European approval of Dario blood glucose monitoring system expected in the near future Company to explore up-listing to national
Read more →DRIOLABSTYLE INNOVATIONS APPOINTS RENOWNED DIABETES EXPERT TO ITS BOARD OF DIRECTORS Appointment of Dr. Itamar Raz of Hadassah Medical Center strengthens board's medical and research expertise CHICAGO and RAMAT GAN, Israel (
LABSTYLE INNOVATIONS APPOINTS RENOWNED TO ITS BOARD OF DIRECTORS Appointment of Dr. Itamar Raz of Hadassah strengthens board's medical and CHICAGO and RAMAT GAN, Israel (June 25, 2013) - LabStyle Innovations Corp. (OTCQB: DRIO), the developer of the Dario smartphone-based di
Read more →DRIOLABSTYLE INNOVATIONS CLOSES $10 MILLION FINANCING Funds will support the anticipated European launch of Dario upon receipt of regulatory clearance RAMAT GAN, Israel (
LABSTYLE INNOVATIONS CLOSES $10 MILLION Funds will support the anticipated European launch of Dario upon receipt of regulatory clearance RAMAT GAN, Israel (May 10, 2013) - LabStyle Innovations Corp. (OTCQB:DRIO), developer of the Dario smartphone-based medical device and dia
Read more →DRIOLABSTYLE INNOVATIONS SIGNS DISTRIBUTION AGREEMENT FOR DARIO IN THE UNITED KINGDOM WITH FARLA MEDICAL Advances strategy for commercialization of smartphone-powered blood glucose monitor upon receipt of CE mark RAMAT GAN,
LABSTYLE INNOVATIONS SIGNS DISTRIBUTION AGREEMENT FOR DARIO IN THE UNITED KINGDOM WITH FARLA MEDICAL Advances strategy for commercialization of smartphone-powered blood glucose monitor upon receipt of CE mark RAMAT GAN, Israel (April 25, 2013) - LabStyle Innovations Corp. (
Read more →Competitive Position
How DRIO ranks across every disease it competes inCompetitive Position is a premium feature
See how DRIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial